[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 188
1. Zhang X, Liang SX, Jia L, Chen N, Fadare O, Schwartz PE, Kong B, Zheng W: Molecular identification of "latent precancers" for endometrial serous carcinoma in benign-appearing endometrium. Am J Pathol; 2009 Jun;174(6):2000-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular identification of "latent precancers" for endometrial serous carcinoma in benign-appearing endometrium.
  • Alteration of p53 is an early event in the development of endometrial serous carcinoma (ESC).
  • We have recently identified a group of benign-looking endometria with p53 overexpression, designated "p53 signatures."
  • The p53 signatures were specifically associated with ESC, frequently found in the benign-appearing endometrium adjacent to the ESC and only rarely in either the endometrium adjacent to endometrioid carcinomas or in non-cancerous uteri.
  • We concluded that p53 gene mutations apparently precede the morphological changes in affected endometrial cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1519-30 [17122507.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4783-91 [17028294.001]
  • [Cites] Int J Gynecol Pathol. 2007 Jan;26(1):38-52 [17197896.001]
  • [Cites] Curr Opin Obstet Gynecol. 2007 Feb;19(1):3-9 [17218844.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Curr Opin Obstet Gynecol. 2008 Feb;20(1):20-5 [18197001.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2263-9 [18369088.001]
  • [Cites] J Surg Oncol. 2008 Sep 1;98(3):207-13 [18623110.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):295-308 [10757340.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4311-4 [11389050.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):207-23 [15306933.001]
  • [Cites] Int J Surg Pathol. 2004 Oct;12(4):319-31 [15494858.001]
  • [Cites] J Natl Cancer Inst. 1981 Jun;66(6):1037-52 [6941039.001]
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):93-108 [7102898.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] J Otolaryngol. 1984 Feb;13(1):1-6 [6716542.001]
  • [Cites] Mod Pathol. 1990 Mar;3(2):120-8 [2326248.001]
  • [Cites] Am J Surg Pathol. 1991 Oct;15(10):965-73 [1928552.001]
  • [Cites] Am J Surg Pathol. 1992 Jun;16(6):600-10 [1599038.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):264-8 [8088602.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1260-7 [7590702.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1268-74 [7590703.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):177-85 [9006334.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1507-14 [9414196.001]
  • [Cites] Genetics. 1998 Apr;148(4):1433-40 [9560363.001]
  • [Cites] Genetics. 1998 Apr;148(4):1483-90 [9560368.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1463-73 [9850172.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):579-82 [15721397.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):907-13 [15829965.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • (PMID = 19435786.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA023074
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2684165
  •  go-up   go-down


2. Pejić S, Todorović A, Stojiljković V, Cvetković D, Lucić N, Radojicić RM, Saicić ZS, Pajović SB: Superoxide dismutase and lipid hydroperoxides in blood and endometrial tissue of patients with benign, hyperplastic and malignant endometrium. An Acad Bras Cienc; 2008 Sep;80(3):515-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superoxide dismutase and lipid hydroperoxides in blood and endometrial tissue of patients with benign, hyperplastic and malignant endometrium.
  • The objective of the present study was to examine changes in activities and levels of copper/zinc superoxide dismutase (CuZnSOD) and lipid hydroperoxides (LOOH) in blood and endometrial tissue of patients diagnosed with uterine myoma, endometrial polypus, hyperplasia simplex, hyperplasia complex and adenocarcinoma endometrii.
  • Decrease of both SOD activity and level was found in endometrium of patients with hyperplasia simplex, hyperplasia complex and adenocarcinoma in comparison to women with polypus or myoma.
  • LOOH level was elevated in both tissues of patients with hyperplasia or adenocarcinoma in comparison to healthy subjects or patients with benign diagnosis.
  • [MeSH-major] Adenocarcinoma. Endometrial Hyperplasia. Endometrial Neoplasms. Leiomyoma. Lipid Peroxides / analysis. Superoxide Dismutase / analysis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Middle Aged. Polyps / blood. Polyps / enzymology. Uterine Neoplasms / blood. Uterine Neoplasms / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18797802.001).
  • [ISSN] 0001-3765
  • [Journal-full-title] Anais da Academia Brasileira de Ciências
  • [ISO-abbreviation] An. Acad. Bras. Cienc.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lipid Peroxides; EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down


3. Rodríguez G, Bilbao C, Ramírez R, Falcón O, León L, Chirino R, Falcón O Jr, Díaz BP, Rivero JF, Perucho M, Díaz-Chico BN, Díaz-Chico JC: Alleles with short CAG and GGN repeats in the androgen receptor gene are associated with benign endometrial cancer. Int J Cancer; 2006 Mar 15;118(6):1420-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alleles with short CAG and GGN repeats in the androgen receptor gene are associated with benign endometrial cancer.
  • The endometrium contains ARs and the androgens have antiproliferative properties in cultured endometrial cancer (EC) cells.
  • Larger CAG repeats of the AR gene give rise to a weaker transcriptional activity and have been found to be associated with endometrial carcinogenesis.
  • To study that possibility, we have genotyped both CAG and GGN polymorphisms of the AR gene in tumor tissue genomic DNA from a series of 204 consecutive patients with EC, and analyzed the results with regard to the pathological features and clinical outcome of patients.
  • When the genotypes of both repeats coexisting in each tumor specimen were taken into consideration, the relationship between the SS-CAG genotype and early stage remained only in the presence of the SS-GGN genotype (43.9% vs 0%, p = 0.01).
  • Our data suggests that short CAG or GGN repeats of the AR gene are associated with a more benign condition of traditional prognostic variables in EC.
  • [MeSH-major] Endometrial Neoplasms / pathology. Polymorphism, Genetic. Receptors, Androgen / genetics. Trinucleotide Repeat Expansion / genetics. Trinucleotide Repeats / genetics

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16187285.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Androgen
  •  go-up   go-down


Advertisement
4. Tanabe K, Matsumoto M, Ikematsu S, Nagase S, Hatakeyama A, Takano T, Niikura H, Ito K, Kadomatsu K, Hayashi S, Yaegashi N: Midkine and its clinical significance in endometrial carcinoma. Cancer Sci; 2008 Jun;99(6):1125-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Midkine and its clinical significance in endometrial carcinoma.
  • The purpose of this study was to determine whether MK was expressed in endometrial carcinoma and to evaluate the clinicopathological significance of serum MK in patients with endometrial carcinoma.
  • Immunohistochemical expression of MK was evaluated in 85 endometrial carcinoma samples and 33 controls.
  • MK expression was significantly higher in the carcinomas than in normal endometrium (P < 0.001).
  • Interestingly, MK expression was highest at the margins of invasion and low in the superficial areas of the tumor samples.
  • Using ELISA, we compared serum MK concentration in 120 endometrial carcinoma patients with the concentration in 46 patients with benign gynecologic tumors.
  • Serum MK value in patients with cancer was significantly higher than that in the patients with benign diseases (P = 0.01).
  • In conclusion, MK immunoreactivity in endometrial carcinoma is significantly higher than in normal endometrium.
  • Thus, MK may be a useful serum biomarker for identifying high risk patients of endometrial carcinoma.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. Nerve Growth Factors / metabolism
  • [MeSH-minor] Enzyme-Linked Immunosorbent Assay. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18422745.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MDK protein, human; 0 / Nerve Growth Factors
  •  go-up   go-down


5. Liu Y: Benign ovarian and endometrial uptake on FDG PET-CT: patterns and pitfalls. Ann Nucl Med; 2009 Feb;23(2):107-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign ovarian and endometrial uptake on FDG PET-CT: patterns and pitfalls.
  • Increased ovarian or endometrial uptake may cause a dilemma in the interpretation of whole body F18-fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging or even misdiagnosis of malignant disease.
  • Knowledge of benign FDG uptake of the ovaries and uterus is important for daily practice of nuclear medicine radiologists.
  • In premenopausal women, increased ovarian or endometrial uptake can be functional or malignant.
  • Benign functional uptake of premenopausal ovaries or uterus is related to the menstrual cycle; therefore, information about the patient's menstrual status is crucial for interpretation.
  • Increased ovarian uptake may also be identified in histologically different benign tumor entities.
  • Nonmenstrual-related endometrial uptake may be present in many benign diseases as well.
  • [MeSH-major] Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Fluorodeoxyglucose F18 / pharmacokinetics. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / metabolism. Ovary / metabolism. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Artifacts. Diagnosis, Differential. Female. Humans. Radiopharmaceuticals / pharmacokinetics

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19225932.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 41
  •  go-up   go-down


6. Goldman NA, Katz EB, Glenn AS, Weldon RH, Jones JG, Lynch U, Fezzari MJ, Runowicz CD, Goldberg GL, Charron MJ: GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma. Mod Pathol; 2006 Nov;19(11):1429-36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma.
  • Regulation of glucose transport facilitator expression has been demonstrated in endometrial tissue and endometrial adenocarcinoma.
  • The following experiments were conducted to quantify and localize the expression of GLUT1 and GLUT8 in benign endometrium and compare this expression to endometrial cancer.
  • Endometrial tissue samples were obtained from random hysterectomy specimens of patients with benign indications for surgery and endometrial cancer.
  • Endometrial samples from 65 women who had undergone hysterectomy were examined (n=38 benign, n=27 malignant).
  • A 44 and a 35.4 kDa immunoreacive species was demonstrated in endometrium and endometrial cancer for GLUT1 and GLUT8, respectively.
  • GLUT8 expression was increased in all tumor subtypes compared to atrophic endometrium (P<0.001).
  • Apical localization by GLUT1 and GLUT8 was demonstrated in endometrial glands.
  • GLUT1 and GLUT8 are expressed in both human endometrium and endometrial cancer.
  • There appears to be a step-wise progression in GLUT1 and GLUT8 expression as tumor histopathology worsens.
  • GLUT1 and GLUT8 may be important markers in tumor differentiation, as well as providing energy to rapidly dividing tumor cells.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Endometrial Neoplasms / chemistry. Endometrium / chemistry. Glucose Transport Proteins, Facilitative / analysis. Glucose Transporter Type 1 / analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16892013.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK47425; United States / NHLBI NIH HHS / HL / HL58119
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transport Proteins, Facilitative; 0 / Glucose Transporter Type 1; 0 / SLC2A1 protein, human; 0 / SLC2A8 protein, human
  •  go-up   go-down


7. Koga T, Ushijima K, Kage M, Ichiki M, Kitajima T, Narita Y, Mizoguchi Y, Hanada M, Ehara R, Nishimura M, Takamori S, Aizawa H: Pulmonary metastasis of endometrial stromal sarcoma. Kurume Med J; 2006;53(3-4):95-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary metastasis of endometrial stromal sarcoma.
  • Morphological characteristics of the thracoscopically resected lung tumors suggested low-grade endometrial stromal sarcoma (ESS), and immunostaining revealed that the tumor cells were positive for progesterone and estrogen receptors, CD10 and vimentin, confirming a diagnosis of ESS.
  • ESS is an uncommon uterine neoplasm, however, may be mistaken as benign tumors such as epithelioid leiomyoma, and occasionally metastasizes to remote organs such as lungs even after long disease-free period, posing diagnostic challenge.
  • [MeSH-major] Endometrial Neoplasms / pathology. Lung Neoplasms / secondary. Sarcoma, Endometrial Stromal / pathology

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317938.001).
  • [ISSN] 0023-5679
  • [Journal-full-title] The Kurume medical journal
  • [ISO-abbreviation] Kurume Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Xie R, Loose DS, Shipley GL, Xie S, Bassett RL Jr, Broaddus RR: Hypomethylation-induced expression of S100A4 in endometrial carcinoma. Mod Pathol; 2007 Oct;20(10):1045-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypomethylation-induced expression of S100A4 in endometrial carcinoma.
  • We hypothesized that S100A4 would be overexpressed in endometrial carcinoma compared to benign endometrium.
  • Quantitative real-time RT-PCR (qRT-PCR) was used to quantify the mRNA level of S100A4 in benign endometrium (n=19), endometrioid adenocarcinoma (n=87), and non-endometrioid tumors (n=21).
  • S100A4 was overexpressed in the grade 3 endometrioid tumors, uterine papillary serous carcinoma, and uterine malignant mixed müllerian tumor.
  • Expression in grade 1 and grade 2 endometrioid tumors was comparable to that of normal endometrium, which was quite low.
  • By immunohistochemistry, S100A4 was expressed in the tumor cell cytoplasm of poorly differentiated tumors, but was not detected in normal endometrial glandular epithelium.
  • In benign endometrium, S100A4 expression was confined to stromal cells.
  • However, methylation of the S100A4 gene was detected in benign endometrium and grade 1 tumors with low S100A4 expression.
  • These methylation results were verified in endometrial cancer cell lines with differential baseline levels of S100A4 protein.
  • [MeSH-major] Adenocarcinoma / genetics. DNA Methylation. Endometrial Neoplasms / genetics. Gene Expression Regulation, Neoplastic. S100 Proteins / genetics
  • [MeSH-minor] Carcinoma, Papillary / genetics. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cell Line, Tumor. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Endometrium / metabolism. Female. Gene Expression. Humans. Immunoenzyme Techniques. Mixed Tumor, Mullerian / genetics. Mixed Tumor, Mullerian / metabolism. Mixed Tumor, Mullerian / pathology. Neoplasm Staging. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17673926.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50CA098258-01; United States / NCI NIH HHS / CN / N01-CN-05127
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / S100 Proteins; 142662-27-9 / S100A4 protein, human
  •  go-up   go-down


9. Kovalenko TF, Vaniusheva OV, Shilov IA, Sosin DV, Sukhoverkhova AS, Kozlova TV, Bokarev IN, Sorokina AV, Ozolinia LA, Patrushev LI: [Promoters of genes MTHFR from patients with hyperhomocysteinemia and PTEN from patients with malignant and benign endometrial and ovarian tumors]. Bioorg Khim; 2006 Jul-Aug;32(4):414-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Promoters of genes MTHFR from patients with hyperhomocysteinemia and PTEN from patients with malignant and benign endometrial and ovarian tumors].
  • Mutational changes in the promoter regions of MTHFR genes from patients with hyperhomocysteinemia and PTEN genes from patients with endometrial and ovarian tumors were studied.
  • A PCR analysis of the minimal promoter region of the tumor suppressor PTEN in the presence of 2-pyrrolidone in 101 patients from Moscow clinics revealed changes in it in patients with endometrial (56%) or ovarian (29%) cancer, as well as in patients with endometrial hyperplasia and benign ovarian tumors (34.6 and 29%, respectively).
  • As a result of the studies, new molecular markers associated with endometrial and ovarian tumors were revealed and a simple and effective method of detection of these markers was developed.
  • [MeSH-major] 5,10-Methylenetetrahydrofolate Reductase (FADH2) / genetics. Biomarkers, Tumor / genetics. Endometrial Neoplasms / genetics. Hyperhomocysteinemia / genetics. Ovarian Neoplasms / genetics. PTEN Phosphohydrolase / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16909866.001).
  • [ISSN] 0132-3423
  • [Journal-full-title] Bioorganicheskaia khimiia
  • [ISO-abbreviation] Bioorg. Khim.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; EC 1.5.1.20 / 5,10-Methylenetetrahydrofolate Reductase (FADH2); EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


10. Norimatsu Y, Miyamoto T, Kobayashi TK, Oda T, Moriya T, Yanoh K, Miyake Y, Ohno E: Utility of thin-layer preparations in endometrial cytology: immunocytochemical expression of PTEN, beta-catenin and p53 for benign endometrial lesions. Diagn Cytopathol; 2008 Apr;36(4):216-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of thin-layer preparations in endometrial cytology: immunocytochemical expression of PTEN, beta-catenin and p53 for benign endometrial lesions.
  • This article focuses on the characteristic features of morphology and molecular biology of PTEN, beta-catenin, and p53 immunocytochemistry in normal endometrium (proliferative, secretory, and atrophic) and endometrial glandular and stromal breakdown (EGBD) using thin-layer specimens.
  • During a 6-month period, 120 endometrial samples were collected directly using the Uterobrush and a thin-layer specimen was prepared.
  • Immunocytochemical expression of PTEN, beta-catenin, and p53 were investigated using 30 cases each of proliferative endometrium (PE), secretory endometrium (SE), atrophic endometrium (AE), and EGBD.PTEN expression of normal endometrial glandular epithelial cells changes with the hormonal status; PE produce very high expression, SE creates attenuation or disappearance of PTEN expression and AE diminished more in comparison with SE.
  • In the current study, the expression manner of PTEN, beta-catenin, and p53 immunocytochemistry was observed in the normal endometrium (PE, SE, and AE) and EGBD.
  • [MeSH-major] Endometrium / cytology. Epithelial Cells / cytology. Epithelial Cells / metabolism. PTEN Phosphohydrolase / metabolism. Tumor Suppressor Protein p53 / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Adult. Aged. Antibodies, Neoplasm / metabolism. Endometrial Neoplasms / pathology. Female. Humans. Immunohistochemistry. Middle Aged

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18335551.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Tumor Suppressor Protein p53; 0 / beta Catenin; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


11. Fujii S, Matsusue E, Kigawa J, Sato S, Kanasaki Y, Nakanishi J, Sugihara S, Kaminou T, Terakawa N, Ogawa T: Diagnostic accuracy of the apparent diffusion coefficient in differentiating benign from malignant uterine endometrial cavity lesions: initial results. Eur Radiol; 2008 Feb;18(2):384-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic accuracy of the apparent diffusion coefficient in differentiating benign from malignant uterine endometrial cavity lesions: initial results.
  • Our purpose is to evaluate the diagnostic accuracy of apparent diffusion coefficient (ADC) measurement in differentiating malignant from benign uterine endometrial cavity lesions.
  • We retrospectively evaluated 25 uterine endometrial cavity lesions in 25 female patients: endometrial carcinoma (n = 11), carcinosarcoma (n = 2), submucosal leiomyoma (n = 8), and endometrial polyp (n = 4).
  • The region of interest was defined within the tumor on T2-weighted EPI image and then manually copied to an ADC map.
  • We compared ADC values between malignant and benign lesions using Student's t-test.
  • The mean and standard deviation of ADC values (x10(-3) mm(2)/s) were as follows: endometrial carcinoma, 0.98+/-0.21; carcinosarcoma, 0.97+/-0.02; submucosal leiomyoma, 1.37+/-0.28; and endometrial polyp, 1.58+/-0.45.
  • The ADC values differed significantly between malignant (0.98+/-0.19) and benign lesions (1.44+/-0.34) (P < 0.01).
  • ADC measurement can provide useful information in differentiating malignant from benign uterine endometrial cavity lesions.
  • [MeSH-major] Carcinosarcoma / diagnosis. Diffusion Magnetic Resonance Imaging / methods. Endometrial Neoplasms / diagnosis. Endometrium / pathology. Leiomyoma / diagnosis. Polyps / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Image Processing, Computer-Assisted. Middle Aged. Reproducibility of Results. Retrospective Studies. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Radiol. 2004 Oct;77(922):851-7 [15482997.001]
  • [Cites] Radiology. 2000 Jan;214(1):47-52 [10644100.001]
  • [Cites] J Magn Reson Imaging. 2006 Aug;24(2):319-24 [16786565.001]
  • [Cites] Radiographics. 1999 Oct;19 Spec No:S131-45 [10517450.001]
  • [Cites] J Magn Reson Imaging. 1999 Jan;9(1):53-60 [10030650.001]
  • [Cites] AJR Am J Roentgenol. 2006 Jul;187(1):181-4 [16794174.001]
  • [Cites] J Magn Reson Imaging. 2005 Aug;22(2):271-8 [16028258.001]
  • [Cites] Radiology. 2005 Jun;235(3):911-7 [15845792.001]
  • [Cites] Radiat Med. 2004 Jul-Aug;22(4):275-82 [15468951.001]
  • [Cites] Eur Radiol. 2007 Jan;17(1):201-4 [16865369.001]
  • [Cites] J Magn Reson Imaging. 2005 Mar;21(3):258-62 [15723379.001]
  • [Cites] J Magn Reson Imaging. 2002 Aug;16(2):172-8 [12203765.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Jun-Jul;27(6):1362-9 [16775298.001]
  • [Cites] AJR Am J Roentgenol. 2001 Aug;177(2):449-54 [11461881.001]
  • [Cites] Magn Reson Imaging. 2002 Jul;20(6):463-70 [12361793.001]
  • [Cites] Magn Reson Med Sci. 2005;4(1):35-42 [16127252.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jan-Feb;29(1):83-6 [15665689.001]
  • [Cites] NMR Biomed. 1995 Nov-Dec;8(7-8):289-96 [8739267.001]
  • [Cites] Radiology. 2005 Jul;236(1):196-203 [15987974.001]
  • [Cites] Eur Radiol. 2007 Jun;17(6):1385-93 [17206421.001]
  • [Cites] J Magn Reson Imaging. 2004 Jul;20(1):97-104 [15221814.001]
  • [Cites] Eur Radiol. 2005 Jan;15(1):71-8 [15538578.001]
  • [Cites] Eur Radiol. 2006 Jul;16(7):1591-8 [16496154.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Aug;27(7):1419-25 [16908550.001]
  • [Cites] J Magn Reson Imaging. 2000 Dec;12(6):1014-9 [11105044.001]
  • [Cites] Eur Radiol. 2002 Nov;12(11):2737-42 [12386766.001]
  • [Cites] Eur Radiol. 2005 Nov;15(11):2244-55 [16228215.001]
  • [Cites] J Magn Reson Imaging. 2007 Sep;26(3):682-7 [17729360.001]
  • [Cites] J Comput Assist Tomogr. 2002 Mar-Apr;26(2):250-6 [11884782.001]
  • [Cites] Radiology. 2002 Jul;224(1):177-83 [12091680.001]
  • [Cites] Magn Reson Imaging. 1999 Dec;17(10):1445-55 [10609993.001]
  • [Cites] Radiology. 2006 Apr;239(1):122-30 [16493012.001]
  • (PMID = 17917730.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Takeuchi M, Matsuzaki K, Nishitani H: Diffusion-weighted magnetic resonance imaging of endometrial cancer: differentiation from benign endometrial lesions and preoperative assessment of myometrial invasion. Acta Radiol; 2009 Oct;50(8):947-53
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted magnetic resonance imaging of endometrial cancer: differentiation from benign endometrial lesions and preoperative assessment of myometrial invasion.
  • BACKGROUND: Uterine endometrial cancer is the most common gynecologic malignancy, and benign endometrial hyperplasia or polyps should be differentiated from endometrial cancer.
  • In evaluating endometrial cancer on magnetic resonance imaging (MRI), the assessment of the depth of myometrial invasion is important because it closely correlates with the patient's prognosis.
  • PURPOSE: To verify the feasibility of diffusion-weighted magnetic resonance imaging (DWI) to distinguish benign and malignant endometrial lesions, and to evaluate myometrial invasion of endometrial cancer.
  • MATERIAL AND METHODS: Sixty-seven endometrial lesions including 45 cancers and 22 benign lesions (hyperplasia and polyps) were evaluated by DWI with apparent diffusion coefficient (ADC) measurement.
  • The staging accuracies of DWI and gadolinium-enhanced T1-weighted images in the assessment of myometrial invasion were evaluated in 33 patients with endometrial cancer.
  • RESULTS: The ADC values (x10(-3) mm(2)/s) in cancer and benign lesions were 0.84+/-0.19 and 1.58+/-0.36, respectively (P<0.01).
  • Coexisting adenomyosis and infiltrative myometrial invasion caused staging errors on gadolinium-enhanced T1-weighted images, whereas DWI could demonstrate the tumor extent correctly.
  • CONCLUSION: DWI provides helpful information in evaluating benign and malignant endometrial lesions.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Endometrial Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Contrast Media. Diagnosis, Differential. Feasibility Studies. Female. Gadolinium. Humans. Middle Aged. Neoplasm Invasiveness. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19724949.001).
  • [ISSN] 1600-0455
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


13. Ashton-Sager A, Paulino AF, Afify AM: GLUT-1 is preferentially expressed in atypical endometrial hyperplasia and endometrial adenocarcinoma. Appl Immunohistochem Mol Morphol; 2006 Jun;14(2):187-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GLUT-1 is preferentially expressed in atypical endometrial hyperplasia and endometrial adenocarcinoma.
  • Although the aberrant expression of GLUT-1 has been reported in a wide spectrum of epithelial malignancies, its possible correlation with the malignant transformation of endometrial epithelium has not been clearly established.
  • The purpose of this study was to evaluate the extent to which benign, hyperplastic, atypical, and malignant endometrial epithelia express GLUT-1.
  • The authors examined the IHC expression of GLUT-1 in cases of proliferative endometrium (n=12), secretory endometrium (n=10), endometrial polyps (n=10), adenomyosis (n=18), simple hyperplasia (n=14), complex hyperplasia without atypia (n=17), complex hyperplasia with atypia (n=17), and adenocarcinoma (n=31).
  • All cases from proliferative endometrium, secretory endometrium, adenomyosis, and simple hyperplasia and 90% (9/10 cases) of the endometrial polyps were negative for GLUT-1.
  • GLUT-1 positivity increased in intensity as the distance of tumor cells to stroma increased.
  • The authors conclude that GLUT-1 is preferentially expressed in complex hyperplasia with atypia and in adenocarcinoma and that GLUT-1 immunostaining is useful in distinguishing benign hyperplasia from hyperplasia strongly associated with malignancy.
  • GLUT-1-mediated glucose transport may allow hypoxic tumor cells distant from stromal blood vessels to survive through glycolysis.
  • These data suggest that the expression of GLUT-1 transporter may be closely related to the malignant transformation of epithelial endometrial tumors by supporting their increased need for glucose metabolism.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785788.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1
  •  go-up   go-down


14. Balasenthil S, Broaddus RR, Kumar R: Expression of metastasis-associated protein 1 (MTA1) in benign endometrium and endometrial adenocarcinomas. Hum Pathol; 2006 Jun;37(6):656-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of metastasis-associated protein 1 (MTA1) in benign endometrium and endometrial adenocarcinomas.
  • Endometrial carcinoma is one of the most common malignancies of the female genital tract.
  • MTA1 expression has been demonstrated in various cancers but has never been explored in endometrial carcinoma.
  • We investigated the expression profile of MTA1 in different stages of benign endometrium as well as in endometrial endometrioid adenocarcinoma using immunohistochemistry and Western blotting.
  • Western blot analysis of 6 tumor specimens showed increased expression of MTA1 in all the tumors analyzed.
  • Immunohistochemical staining performed on tumor microarray containing 70 endometrial endometrioid adenocarcinomas of various grades showed increased expression of MTA1 in 53 (75.7%) tumors.
  • Our results suggest a potential role of MTA1 in endometrial carcinomas.
  • [MeSH-major] Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Endometrium / metabolism. Gene Expression. Histone Deacetylases / metabolism. Repressor Proteins / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cell Nucleus / metabolism. Cytoplasm / metabolism. Female. Humans. Immunohistochemistry. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16733204.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 098823
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Repressor Proteins; EC 3.5.1.- / Mta1 protein, human; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


15. Czekierdowski A, Czekierdowska S, Czuba B, Cnota W, Sodowski K, Kotarski J, Zwirska-Korczala K: Microvessel density assessment in benign and malignant endometrial changes. J Physiol Pharmacol; 2008 Sep;59 Suppl 4:45-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microvessel density assessment in benign and malignant endometrial changes.
  • Tumor angiogenesis is believed to be a prognostic indicator associated with tumor growth and metastasis.
  • Microvessel density (MVD) assessment with common endothelial markers such as CD34 has been found to influence prognosis among endometrial carcinoma patients.
  • The aim of this study was to evaluate the quantification of angiogenesis by assessing MVD in endometrial lesions when comparing the performance of anti-CD34 and anti-CD105 in women with benign and malignant endometrial changes.
  • The study included 58 women (37 postmenopausal) with normal, hyperplastic and malignant endometrium in which preoperative transvaginal sonography was performed.
  • Histological results of the removed endometrium were correlated with MVD assessed in "hot areas" where high densities of microvessels were detected within tumoral tissue.
  • Endometrial cancer was confirmed in 37 women (3 premenopausal).
  • Benign hyperplasia (14 cases), secretory or proliferative endometrium (5 cases) or endometrial atrophy (2 cases) was found in the remaining women.
  • Median MVD assessed with CD34 was almost twice higher in women with endometrial cancer than in women with benign endometrium (CD34 MVD = 41.8 vs. 27.6, p=0.004).
  • In cases of CD105 MVD significant differences between women with benign and malignant endometrial changes were also found (CD105 MVD = 11.8, vs. 6.4; p=0.00007).
  • In conclusion, transition from endometrial hyperplasia to endometrial cancer appears to be accompanied by microvessel density changes.
  • MVD assessed with both CD34 and CD105 antibodies could be used as a potential prognostic factor in women with endometrial cancer.
  • Our study showed that endoglin, by staining the proliferating microvessels could be more specific and sensitive marker for tumor neoangiogenesis than the more commonly used marker, CD34.
  • [MeSH-major] Biomarkers, Tumor / analysis. Endometrial Neoplasms / blood supply. Microvessels. Neovascularization, Pathologic / ultrasonography
  • [MeSH-minor] Antigens, CD / analysis. Antigens, CD / biosynthesis. Antigens, CD34 / analysis. Antigens, CD34 / biosynthesis. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Receptors, Cell Surface / analysis. Receptors, Cell Surface / biosynthesis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18955753.001).
  • [ISSN] 1899-1505
  • [Journal-full-title] Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  • [ISO-abbreviation] J. Physiol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / ENG protein, human; 0 / Receptors, Cell Surface
  •  go-up   go-down


16. Barroeta JE, Pasha TL, Acs G, Zhang PJ: Immunoprofile of endocervical and endometrial stromal cells and its potential application in localization of tumor involvement. Int J Gynecol Pathol; 2007 Jan;26(1):76-82
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoprofile of endocervical and endometrial stromal cells and its potential application in localization of tumor involvement.
  • To evaluate and compare the immunophenotype of endocervical and endometrial stromal cells and to asses its potential application in tumor localization.
  • Paraffin sections of benign endocervix (n = 24), benign endometrium (n = 33), endocervical adenocarcinoma (n = 9), endometrial carcinoma (n = 13), and endometrial hyperplasia (n = 16) were stained with antibodies to CD10, Wilms Tumor-1, CD34, smooth muscle actin, and factor XIIIa by immunohistochemistry.
  • Endocervical stromal cells (ECSC) in either benign or malignant cervical epithelial lesions were predominantly CD34/CD10 (CD34 dominant immunophenotype).
  • Endometrial stromal cells (EMSCs) in either benign or malignant epithelial lesions were primarily CD34/CD10 (CD10 dominant immunophenotype).
  • Expression of Wilms Tumor-1 was decreased in EMSC of the EMCA when compared to their counterpart in endometrial hyperplasia.
  • The functional status of the endometrium had no effect on the immunoprofile.
  • The pattern of CD34 and CD10 immunostaining in stromal cells might be helpful in determining tumor involvement in uterine and cervical sites.
  • [MeSH-major] Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Stromal Cells / metabolism. Stromal Cells / pathology. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197901.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Quddus MR, Ologun BA, Sung CJ, Steinhoff MM, Lawrence WD: Utility of PTEN expression of endometrial "surface epithelial changes" and underlying atypical endometrial hyperplasia. Int J Gynecol Pathol; 2009 Sep;28(5):471-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of PTEN expression of endometrial "surface epithelial changes" and underlying atypical endometrial hyperplasia.
  • Surface epithelial changes (SECs) have been reported to be associated with endometrial carcinoma in about 49% of cases.
  • They have also been seen to be associated with endometrial hyperplasia.
  • Although morphologically benign, these lesions are considered a marker for underlying malignancy.
  • PTEN has been reported to be altered in endometrial carcinomas and endometrial precancers where no morphologic changes are appreciated.
  • The current study aims to investigate PTEN status in the endometrial SECs.
  • Thirty-two cases of endometrial biopsy are divided into 2 groups: group 1 had 18 cases of SEC and underlying endometrial atypical hyperplasia and group 2 had 14 cases of SEC alone.
  • Overall, PTEN alteration (NULL) was found in 12 of the 32 cases of endometrial samples (37.5%) examined.
  • In group 1, 10 of the 18 cases (56%) of atypical endometrial hyperplasia with "SECs" showed PTEN NULL.
  • Two other cases (20%) had atypical endometrial hyperplasia only.
  • These 2 patients were followed for 26 and 63 months, respectively, and subsequent endometrial biopsies and pap smears were negative.
  • Presence of PTEN NULL phenotype in SECs and associated endometrial hyperplasia does not necessarily predict an increased incidence of endometrioid carcinoma in subsequent follow-up.
  • However, absence of PTEN NULL phenotype in SECs alone may predict a benign follow-up.
  • [MeSH-major] Biomarkers, Tumor / analysis. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / pathology. Endometrium / pathology. PTEN Phosphohydrolase / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19696618.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


18. Coosemans A, Moerman P, Verbist G, Maes W, Neven P, Vergote I, Van Gool SW, Amant F: Wilms' tumor gene 1 (WT1) in endometrial carcinoma. Gynecol Oncol; 2008 Dec;111(3):502-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wilms' tumor gene 1 (WT1) in endometrial carcinoma.
  • OBJECTIVE: Wilms' tumor gene (WT1), located on chromosome 11, encodes a transcription factor that contributes to the carcinogenesis of uterine sarcomas.
  • To expand the knowledge on the biological role of WT1 in other uterine cancers, we focused on its detection in endometrial carcinoma.
  • METHODS: In total, 36 paraffin-embedded tumors were available for WT1 immunohistochemical (IHC) analysis including endometrial endometrioid carcinoma (n=24), serous carcinoma (n=9) and clear cell carcinoma (n=3).
  • Three slides from different sites of the tumor were analysed.
  • To compare, WT1 expression was also evaluated by IHC in benign endometrium (12) and benign endometrial polyps (5).
  • RESULTS: WT1 positivity was noticed in tumor cells and endothelial cells, lining the intratumoral blood vessels.
  • Comparing the staining patterns of the 3 different bioptic sites, tumor heterogeneity was demonstrated in the majority (72%) of samples.
  • CONCLUSION: Although WT1 is expressed in a majority of endometrial carcinomas, a heterogeneous staining pattern is observed.
  • [MeSH-major] Endometrial Neoplasms / genetics. Genes, Wilms Tumor
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Aged. Biopsy. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Female. Humans. Immunohistochemistry. Neoplasm Staging. Reverse Transcriptase Polymerase Chain Reaction. WT1 Proteins / biosynthesis. WT1 Proteins / genetics

  • Genetic Alliance. consumer health - Wilms' tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18929401.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / WT1 Proteins
  •  go-up   go-down


19. Akbulut M, Zekioglu O, Terek MC, Ozdemir N: Lipoadenofibroma of the endometrium: a rare variant of benign mullerian mixed tumor. Arch Gynecol Obstet; 2008 Sep;278(3):283-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipoadenofibroma of the endometrium: a rare variant of benign mullerian mixed tumor.
  • OBJECTIVE: Adenofibroma is a form of mixed mesodermal tumor in which epithelial and stromal components are benign, and usually arises in the endometrium of postmenopausal women.
  • We report a case of lipoadenofibroma of the endometrium that appeared as an intracavitary mass, which is very unusual because endometrioid adenofibroma rarely contains mature adipose tissue, only the second such case described in detail.
  • CASE: An endometrial polypoid mass measuring 1,5 cm with maximum diameter was found incidentally during total abdominal hysterectomy for keratinizing large cell carcinoma of the cervix in a 60-year-old woman.
  • The endometrial polypoid mass was found to be a lipoadenofibroma composed predominantly of collagenated fibrous stroma populated by cystically dilated and occasionally crowded glands lined with proliferative endometrium, intermingled with abundant mature adipose tissue.
  • CONCLUSION: We suggest that uterine adenofibromas with lipomatous areas belong to the family of mixed tumor of Mullerian origin.
  • [MeSH-major] Adenofibroma / pathology. Endometrial Neoplasms / pathology. Mixed Tumor, Mullerian / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18236054.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Pavlakis K, Messini I, Vrekoussis T, Panoskaltsis T, Chrissanthakis D, Yiannou P, Stathopoulos EN: PTEN-loss and nuclear atypia of EIN in endometrial biopsies can predict the existence of a concurrent endometrial carcinoma. Gynecol Oncol; 2010 Dec;119(3):516-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PTEN-loss and nuclear atypia of EIN in endometrial biopsies can predict the existence of a concurrent endometrial carcinoma.
  • AIM: The objective of the present study was to evaluate whether nuclear atypia or PTEN-loss in endometrial intraepithelial neoplasia (EIN), could help to predict in endometrial curettage material, the prevalence of concurrent carcinoma in hysterectomy specimens.
  • MATERIALS AND METHODS: This retrospective single-institution study included women who were diagnosed with endometrial hyperplasia (simple or complex) and underwent hysterectomy within 12weeks from the initial diagnosis without interval treatment.
  • All endometrial curettage slides were reviewed by three experienced pathologists and only cases that fulfilled the criteria of EIN were used for further analysis.
  • RESULTS: Out of 83 cases that were enrolled in the study, 33 (39.76%), had a concurrent endometrial carcinoma.
  • Nuclear atypia in EIN cases with a final histology of endometrial cancer was found in 31 out of 33 cases (93.94%) but only in 27 out of 50 benign cases (54%).
  • There was no PTEN-loss in 8 out of 33 EIN cases (24.24%) that proved to be cancer and 22 out of 50 EIN cases (44%) that proved to be benign.
  • Either atypia or PTEN-loss or both were found in 33/33 (100%) cancer cases and in 39/50 (78%) benign cases; this difference was statistically significant (Fisher exact test, p < 0.05).
  • CONCLUSION: PTEN-loss, as an independent variable, was not found to be a predictor of endometrial cancer in the final histology.
  • However, biopsies presented with EIN, featuring nuclear atypia and recognized as PTEN-null are more likely to be finally diagnosed with endometrial cancer.
  • [MeSH-major] Endometrial Hyperplasia / enzymology. Endometrial Neoplasms / enzymology. PTEN Phosphohydrolase / deficiency
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / deficiency. Biomarkers, Tumor / metabolism. Biopsy. Female. Humans. Immunohistochemistry. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20833413.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


21. Karpf EF, Poetsch B, Langner C, Nogales FF, Regauer S: Endometrial stromal nodule embedded into term placenta. APMIS; 2007 Nov;115(11):1302-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial stromal nodule embedded into term placenta.
  • A 28-year-old patient presented with a 5 cm endometrial stromal tumor situated at the uteroplacental interface, which was diagnosed ultrasonographically at the 28th week of pregnancy.
  • The tumor was asymptomatic and closely attached to the decidua; after a normal term delivery, it was revealed to be embedded within the placenta.
  • Microscopically, the neoplasm had a high mitotic rate and characteristic features of endometrial stromal tumor, such as CD10, progesterone receptor positivity, and an expansile linear, non-infiltrative pushing border.
  • In conclusion, the lesion was considered a benign endometrial stromal nodule with an unusual morphology and increased proliferation rate due to the hormonal stimuli of pregnancy.
  • [MeSH-major] Endometrial Neoplasms / ultrasonography. Gastrointestinal Stromal Tumors / ultrasonography. Placenta / pathology. Pregnancy Complications, Neoplastic / ultrasonography

  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18092965.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


22. Ni Bhriain H, Trovik J, Wik E, Stefansson IM, Akslen LA, Salvesen HB, Staff AC: Plasma calprotectin concentrations in women with endometrial carcinoma. Gynecol Oncol; 2009 Sep;114(3):491-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma calprotectin concentrations in women with endometrial carcinoma.
  • OBJECTIVES: There is a lack of circulating markers to predict disease outcome, therapy effect and monitoring for disease recurrence in endometrial cancer.
  • The aim of this study was to explore whether plasma concentration of the inflammatory marker calprotectin is elevated in endometrial cancer and related to clinical parameters.
  • METHODS: Calprotectin in EDTA-plasma samples from women with primary endometrial carcinoma (n=194), from healthy premenopausal (n=20) and postmenopausal (n=20) women was analyzed with ELISA.
  • RESULTS: Median plasma calprotectin concentration was elevated in the patient group of endometrial cancer (3415 microg/L) as compared to the healthy premenopausal (832 microg/L) and postmenopausal groups (868 microg/L), both p<0.001.
  • Also, median calprotectin concentration was elevated in the endometrial cancer group as compared to women with invasive ovarian cancer, borderline ovarian tumor and benign ovarian tumors.
  • Calprotectin plasma concentration correlated significantly with poor survival and high FIGO stage in endometrial carcinoma.
  • CONCLUSION: Calprotectin is elevated in plasma of women with endometrial carcinoma.
  • [MeSH-major] Endometrial Neoplasms / blood. Leukocyte L1 Antigen Complex / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. ROC Curve. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19577278.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Leukocyte L1 Antigen Complex
  •  go-up   go-down


23. Fadare O, Liang SX, Ulukus EC, Chambers SK, Zheng W: Precursors of endometrial clear cell carcinoma. Am J Surg Pathol; 2006 Dec;30(12):1519-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursors of endometrial clear cell carcinoma.
  • The recognition of morphologically identifiable lesions which may confer an increased risk for subsequent development of an invasive malignancy offers an opportunity to investigate and better understand the molecular-genetic etiopathogenesis of the well-developed tumor, and potentially, to administer a therapeutic intervention before its development.
  • In contrast to uterine endometrioid and serous carcinomas, very little is known about the potential precursor lesions of endometrial clear cell carcinoma (ECCC).
  • In our routine practice, we have noted the presence of a spectrum of atypical glandular changes in the endometria adjacent to ECCC or endometrial carcinomas with a clear cell component, which on the basis of current criteria, would not qualify for any specific designation.
  • Thirty archived cases of pure ECCC (n=14) or mixed endometrial carcinomas with a >10% clear cell component (n=16) were retrieved and the "normal" endometria adjacent to the malignancies were evaluated in detail.
  • Thirty-eight benign uteri and 30 uteri with classic endometrial endometrioid carcinoma (EEC) served as controls.
  • The lesions were typically isolated glands or surface epithelium (within an otherwise normal endometrial region) that displayed cytoplasmic clarity and/or eosinophilia with varying degrees of nuclear atypia.
  • In contrast, PPL were identified neither in the benign uteri nor in endometrioid carcinoma control groups (P<0.001).
  • The immunohistochemical expression of p53, mib-1, estrogen receptor (ERs), and progesterone receptor in the benign endometria, ECCC, and the PPL were evaluated on all 27 cases.
  • The mean p53 scores for the benign endometria, PPL, and ECCC were 0, 4.5, and 6.2, respectively.
  • ER/progesterone receptor indices for benign endometria, PPL, and carcinoma were 90/80, 21.52/4.61, and 11/4, respectively.
  • The PPL described herein have a morphologic and immunophenotypic profile which seems to be distinct from both the benign endometria in which they reside and the adjacent areas of ECCC.
  • The high frequency of association of these lesions with ECCC, their frequent occurrence as isolated lesions within otherwise "benign-appearing" endometria, and their continuous spectrum of nuclear atypia from minimum (grade 1, cytologic atypia falls short of ECCC cells) to maximum (grade 3, cytologically identical to ECCC cells), argues in favor of our hypothesis that these may represent precursor lesions of ECCC.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometrial Neoplasms / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Endometrium / chemistry. Endometrium / pathology. Exocrine Glands / chemistry. Exocrine Glands / pathology. Female. Humans. Immunoenzyme Techniques. Middle Aged. Single-Blind Method

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122507.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


24. Junaid I, Paz R, Salihu HM, Sharma PP, Aliyu ZY: Pseudo-Meig's syndrome with multiple synchronous benign and malignant pelvic tumors. Arch Gynecol Obstet; 2006 Feb;273(5):315-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudo-Meig's syndrome with multiple synchronous benign and malignant pelvic tumors.
  • BACKGROUND: Meig's and Pseudo-Meig's syndromes have been reported in association with several malignancies but the concomitant existence of multiple synchronous benign and malignant tumors in association with Pseudo-Meigs' syndrome has not been reported in the published literature.
  • Histological examination confirmed a right ovarian carcinoid tumor embedded within a mature cystic teratoma while the left ovary, fallopian tube and the uterus contained a poorly differentiated adenocarcinoma of the endometrium.
  • CONCLUSION: This is the first case report of Pseudo-Meig's syndrome in association with ovarian carcinoid tumor and multiple synchronous benign and malignant pelvic tumors.
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Asthma / complications. CA-125 Antigen / blood. Carcinoid Tumor / complications. Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Endometrial Neoplasms / complications. Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Fallopian Tube Neoplasms / complications. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / surgery. Female. Humans. Hydrothorax / complications. Middle Aged. Ovarian Neoplasms / complications. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Teratoma / complications. Teratoma / pathology. Teratoma / surgery. Uterine Neoplasms / complications. Uterine Neoplasms / pathology. Uterine Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16136360.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


25. Francz M: [The premalignant disease of the endometrium: endometrial intraepithelial neoplasia]. Magy Onkol; 2008 Mar;52(1):35-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The premalignant disease of the endometrium: endometrial intraepithelial neoplasia].
  • [Transliterated title] Az endometrium rákmegelozo állapota: endometrialis intraepithelialis neoplasia.
  • The WHO 1994 classification for endometrial hyperplasias is based on the morphologic features of the lesions.
  • Modern molecular data related to endometrial tumorigenesis and precise computerized morphometric analysis have identified the lesion that may be considered as a precursor of endometrioid adenocarcinoma.
  • By definition, this endometrial intraepithelial neoplasia (EIN) is a clonal proliferation of architecturally and cytologically altered endometrial glands which are prone to malignant transformation to endometrioid (type I) endometrial adenocarcinoma.
  • The morphometric basis of EIN diagnosis is the D-score (DS), which is a logical combination of three morphometric features that represent the glandular complexity, glandular volume and cytological alterations.
  • Hyperplasia cases that do not fit into the EIN categories are considered as benign or hormonal endometrial hyperplasia.
  • This is the theoretical basis of a new classification system in premalignant endometrial diseases.
  • [MeSH-major] Endometrial Neoplasms / diagnosis. Endometrium / pathology. Precancerous Conditions / classification
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Hyperplasia / therapy. PTEN Phosphohydrolase / analysis. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18403295.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Number-of-references] 19
  •  go-up   go-down


26. Chen N, Yi X, Abushahin N, Pang S, Zhang D, Kong B, Zheng W: Nrf2 expression in endometrial serous carcinomas and its precancers. Int J Clin Exp Pathol; 2010 Dec 24;4(1):85-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nrf2 expression in endometrial serous carcinomas and its precancers.
  • Endometrial serous carcinoma (ESC) is the most aggressive subtype of endometrial cancer.
  • The aim of this study is to determine the Nrf2 expression in benign endometrium (n=28), endometrial cancers (n=122) as well as their precursor lesions (n=81) trying to see whether Nrf2 has any diagnostic usage and is potentially involved in endometrial carcinogenesis.
  • Among the malignant cases, Nrf2 was positive in 28 (68%) of 50 ESCs, which was significantly more than in 3 (6%) of 50 endometrioid carcinomas (p < 0.001) and 2 (13%) of 15 clear cell carcinomas (p = 0.001) and other histologic types of endometrial cancers.
  • Among endometrial precursor lesions, both serous endometrial glandular dysplasia (EmGD, 40%) and serous endometrial intraepithelial carcinoma (EIC, 44%) showed a significantly higher Nrf2 expression than that in atypical endometrial hyperplasia or endometrial intraepithelial neoplasia (0%), clear cell EmGD (10%), and clear cell EIC (25%), respectively.
  • We conclude that Nrf2 overexpression is closely associated with endometrial neoplasms with serous differentiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mutat Res. 2005 Dec 11;591(1-2):93-102 [16054659.001]
  • [Cites] Mol Cell. 2009 Jun 26;34(6):663-73 [19560419.001]
  • [Cites] J Pathol. 2000 Mar;190(4):462-9 [10699996.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):295-308 [10757340.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):797-806 [10843281.001]
  • [Cites] Int J Gynecol Pathol. 2000 Oct;19(4):301-9 [11109157.001]
  • [Cites] Am J Respir Cell Mol Biol. 2002 Feb;26(2):175-82 [11804867.001]
  • [Cites] J Clin Pathol. 2002 May;55(5):326-31 [11986334.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):213-23 [14747944.001]
  • [Cites] Biochem J. 2004 Jun 1;380(Pt 2):515-21 [14960151.001]
  • [Cites] Mol Cell Biol. 2004 Aug;24(16):7130-9 [15282312.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):207-23 [15306933.001]
  • [Cites] Int J Surg Pathol. 2004 Oct;12(4):319-31 [15494858.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] J Natl Cancer Inst. 1991 Mar 20;83(6):405-16 [1999848.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1260-7 [7590702.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1463-73 [9850172.001]
  • [Cites] Genes Dev. 1999 Jan 1;13(1):76-86 [9887101.001]
  • [Cites] J Clin Invest. 2004 Nov;114(9):1248-59 [15520857.001]
  • [Cites] Mol Cell Biol. 2004 Dec;24(24):10941-53 [15572695.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):579-82 [15721397.001]
  • [Cites] J Exp Med. 2005 Jul 4;202(1):47-59 [15998787.001]
  • [Cites] Mol Cell. 2006 Mar 3;21(5):689-700 [16507366.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4783-91 [17028294.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1519-30 [17122507.001]
  • [Cites] PLoS Med. 2006 Oct;3(10):e420 [17020408.001]
  • [Cites] Drug Metab Rev. 2006;38(4):769-89 [17145701.001]
  • [Cites] Neurotoxicology. 2006 Dec;27(6):1094-100 [16959318.001]
  • [Cites] Int J Gynecol Pathol. 2007 Jan;26(1):38-52 [17197896.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2007;47:89-116 [16968214.001]
  • [Cites] Free Radic Biol Med. 2007 Feb 15;42(4):433-45 [17275675.001]
  • [Cites] Pathology. 2007 Feb;39(1):46-54 [17365822.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Nov 3;362(4):816-21 [17822677.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Eur J Pharmacol. 2009 Oct 12;620(1-3):138-44 [19698707.001]
  • [Cites] J Pathol. 2010 Mar;220(4):446-51 [19967722.001]
  • [Cites] Toxicol Appl Pharmacol. 2010 Apr 1;244(1):37-42 [19538984.001]
  • [Cites] Toxicol Appl Pharmacol. 2010 Apr 1;244(1):84-97 [19716833.001]
  • [Cites] Diabetes. 2010 Apr;59(4):850-60 [20103708.001]
  • [Cites] Cancer Res. 2010 Jul 1;70(13):5486-96 [20530669.001]
  • [Cites] Free Radic Biol Med. 2010 Dec 1;49(11):1603-16 [20840865.001]
  • [Cites] Curr Opin Obstet Gynecol. 2008 Feb;20(1):20-5 [18197001.001]
  • [Cites] Cancer Lett. 2008 Feb 18;260(1-2):96-108 [18036733.001]
  • [Cites] Am J Obstet Gynecol. 2008 Feb;198(2):218.e1-6 [18226630.001]
  • [Cites] Carcinogenesis. 2008 Jun;29(6):1235-43 [18413364.001]
  • [Cites] Free Radic Biol Med. 2008 Sep 1;45(5):651-8 [18572023.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7975-84 [18829555.001]
  • [Cites] Pharmacol Res. 2008 Nov-Dec;58(5-6):262-70 [18838122.001]
  • [Cites] Mol Carcinog. 2009 Feb;48(2):91-104 [18618599.001]
  • [Cites] Trends Biochem Sci. 2009 Apr;34(4):176-88 [19321346.001]
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):287-90 [10684697.001]
  • (PMID = 21228930.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA023074; United States / NIEHS NIH HHS / ES / R01 ES015010; United States / NCI NIH HHS / CA / P30 CA23074
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NF-E2-Related Factor 2; 0 / NFE2L2 protein, human
  • [Other-IDs] NLM/ PMC3016106
  • [Keywords] NOTNLM ; Nrf2 / endometrial cancer / endometrial glandular dysplasia / endometrial serous carcinoma / precancer
  •  go-up   go-down


27. Yoshizaki T, Enomoto T, Nakashima R, Ueda Y, Kanao H, Yoshino K, Fukumoto M, Yoneda Y, Buzard GS, Murata Y: Altered protein expression in endometrial carcinogenesis. Cancer Lett; 2005 Aug 26;226(2):101-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered protein expression in endometrial carcinogenesis.
  • We have discovered several protein biomarkers that are altered during carcinogenesis of the human uterine endometrium.
  • Proteins prepared from 19 endometrial carcinomas (Group A), and 20 normal endometria obtained from benign gynecological conditions (Group B), were investigated by Surface Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (SELDI-TOF-MS).
  • These proteins are thus potential biomarkers for detection of endometrial carcinoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Endometrial Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16039949.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


28. Jia L, Liu Y, Yi X, Miron A, Crum CP, Kong B, Zheng W: Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res; 2008 Apr 15;14(8):2263-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma.
  • PURPOSE: Endometrial glandular dysplasia (EmGD) has been recently proposed to be a putative precursor to endometrial serous carcinoma (ESC).
  • EXPERIMENTAL DESIGN: The tumor suppressor p53 gene was sequenced from serial samples of benign and neoplastic endometria with serous differentiation.
  • The study group contained 15 neoplastic uteri and the control group had 12 age-matched benign uteri.
  • A total of 139 informative samples were obtained, including 55 resting endometrium, 37 EmGD, 25 serous endometrial intraepithelial carcinoma (EIC), and 22 ESC.
  • RESULTS: The mutations of p53 were detected in 0%, 43%, 72%, and 96% in resting endometrium, EmGD, serous EIC, and ESC, respectively.
  • Mutation of p53 gene is probably one of the most important factors to initiate the endometrial serous carcinogenesis.
  • Correct identification of EmGD will provide us an opportunity of early diagnosis and a potentially effective therapeutic modality to control ESC.
  • [MeSH-major] Cystadenocarcinoma, Serous / genetics. Endometrial Neoplasms / genetics. Endometrium / pathology. Genes, p53. Mutation. Precancerous Conditions / genetics
  • [MeSH-minor] Aged. Base Sequence. Female. Humans. Middle Aged. Molecular Sequence Data. Tumor Suppressor Protein p53 / analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18369088.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA23074
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


29. Bettaieb I, Mekni A, Bellil K, Haouet S, Bellil S, Kchir N, Chelly H, Zitouna M: Endometrial adenofibroma: a rare entity. Arch Gynecol Obstet; 2007 Mar;275(3):191-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenofibroma: a rare entity.
  • Endometrial adenofibroma is an uncommon mullerian mixed tumor composed of benign epithelial and mesenchymal components.
  • This tumor must be distinguished from other malignant lesions of the uterus, particularly adenosarcoma.
  • The authors report three cases of endometrial adenofibroma and discuss their clinical and histopathologic features.
  • [MeSH-major] Adenofibroma / pathology. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16858575.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


30. Zalutskiĭ IV, Vishnevskaia EE, Kurian LM: [Methodologic and organizational principles of selective screening for cervical, endometrial and ovarian carcinoma]. Vopr Onkol; 2006;52(1):74-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Methodologic and organizational principles of selective screening for cervical, endometrial and ovarian carcinoma].
  • Data are presented on screening for cervical (CC), endometrial (UC) and ovarian (OC) carcinoma carried out in the Republic of Belarus as well as a discussion of logistic and methodologic aspects of the problem.
  • Local "centers for prevention and early diagnosis of reproductive organ tumors" form the backbone of the national system.
  • Consequently, the share of endometrial hyperplasia cases rose 3.5-fold, uterine myoma--3-fold and adenomyosoma--1.5-fold. identified atypical endometrial hyperplasia, in situ cancer and endometrial stage I in "clinically healthy" women.
  • The rates of detection of such tumor-like ovarian formations as follicular, lutein, endometrioid and para-ovarian cysts increased 2.3-fold, benign tumors--2.2-fold and polycystosis--twofold.
  • [MeSH-major] Cancer Care Facilities / organization & administration. Endometrial Neoplasms / epidemiology. Mass Screening / methods. Mass Screening / organization & administration. Ovarian Neoplasms / epidemiology. Uterine Cervical Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Cysts / diagnosis. Endometrial Hyperplasia / epidemiology. Female. Humans. Incidence. Middle Aged. Republic of Belarus. Uterine Cervical Dysplasia / epidemiology


31. Monaco E 3rd, Kondziolka D, Mongia S, Niranjan A, Flickinger JC, Lunsford LD: Management of brain metastases from ovarian and endometrial carcinoma with stereotactic radiosurgery. Cancer; 2008 Nov 1;113(9):2610-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of brain metastases from ovarian and endometrial carcinoma with stereotactic radiosurgery.
  • BACKGROUND: Metastases to the brain from ovarian and endometrial carcinoma are uncommon and to the authors' knowledge consensus regarding optimal management is lacking.
  • Stereotactic radiosurgery (SRS) has proven useful for the treatment of many benign and malignant brain tumors.
  • In the current study, the authors evaluated outcomes after SRS in patients with ovarian and endometrial carcinoma.
  • Six patients had endometrial carcinoma, whereas 21 patients had ovarian carcinoma.
  • The median survival was 7 months after the initial diagnosis of brain metastasis and 5 months after SRS.
  • The 1-year survival rate after radiosurgery was 15% and that from the diagnosis of brain metastases was 22%.
  • CONCLUSIONS: SRS is an acceptable choice for the treatment of brain metastases resulting from ovarian and endometrial carcinoma, and provides local tumor control with limited morbidity.
  • [MeSH-major] Brain Neoplasms / surgery. Cranial Irradiation. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology. Radiosurgery
  • [MeSH-minor] Disease-Free Survival. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18780313.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Giordano G, D'Adda T, Gnetti L, Merisio C, Raboni S: Transitional cell carcinoma of the endometrium associated with benign ovarian brenner tumor: a case report with immunohistochemistry molecular analysis and a review of the literature. Int J Gynecol Pathol; 2007 Jul;26(3):298-304
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma of the endometrium associated with benign ovarian brenner tumor: a case report with immunohistochemistry molecular analysis and a review of the literature.
  • Transitional cell carcinoma of the endometrium (TCCE) is a subtype of endometrial carcinoma, characterized by a prominent papillary pattern, resembling the papillary carcinoma of the urothelium.
  • This neoplasm is very rare, with only 13 cases reported in the international literature.
  • In this paper, a new case of TCCE associated with benign ovarian Brenner tumor is described.
  • Moreover, immunohistochemical and molecular studies are carried out in the effort to establish the phenotype and etiology of this rare neoplasm.
  • The molecular study, by polymerase chain reaction (PCR) failing to reveal the presence of HPV DNA, demonstrates that neither the TCCE nor the ovarian Brenner tumor is caused by an HPV infection.
  • The association of TCCE with benign ovarian Brenner tumor could be a coincidental event.
  • In our view, other cases of TCCE associated with ovarian Brenner tumor should be reported to confirm the last 2 hypotheses.
  • [MeSH-major] Brenner Tumor / pathology. Carcinoma, Transitional Cell / pathology. Endometrial Neoplasms / pathology
  • [MeSH-minor] DNA, Neoplasm / chemistry. DNA, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Middle Aged. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17581415.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


33. Norimatsu Y, Moriya T, Kobayashi TK, Sakurai T, Shimizu K, Tsukayama C, Ohno E: Immunohistochemical expression of PTEN and beta-catenin for endometrial intraepithelial neoplasia in Japanese women. Ann Diagn Pathol; 2007 Apr;11(2):103-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of PTEN and beta-catenin for endometrial intraepithelial neoplasia in Japanese women.
  • Currently, the World Health Organization (WHO) classifies endometrial hyperplasia as a premalignant disease.
  • However, one of the problems in the current WHO endometrial hyperplasia schema is that it is not always a reproducible classification system.
  • Subsequently, the alternative molecular genetics and morphometric-based classification, referred to as the endometrial intraepithelial neoplasia (EIN) classification system, has been proposed.
  • We reclassified endometrial lesions in Japanese women using the EIN category and compared them with the results of PTEN as well as beta-catenin immunohistochemistry.
  • A total of 117 cases that were initially diagnosed as endometrial hyperplasia according to WHO classification were reevaluated histopathologically by the EIN diagnosis category.
  • They were classified into 38 EIN and 32 benign architectural changes of unopposed estrogen (BAC), and 47 cases were excluded.
  • In addition, for comparison, we examined 20 cases of normal proliferative endometrium (NPE).
  • Endometrial intraepithelial neoplasia was significantly less frequently positive for PTEN than NPE (P < .025).
  • [MeSH-major] Carcinoma in Situ / metabolism. Endometrial Neoplasms / metabolism. PTEN Phosphohydrolase / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Cell Nucleus / pathology. Endometrium / metabolism. Female. Humans. Immunoenzyme Techniques. Japan. Middle Aged. Premenopause

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17349568.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / beta Catenin; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


34. Mangioni S, Viganò P, Florio P, Borghi O, Vignali M, Petraglia F, Di Blasio AM: Effect of activin A on tumor necrosis factor-alpha/intercellular adhesion molecule-1 pathway in endometrial stromal cells. Eur J Obstet Gynecol Reprod Biol; 2005 Dec 1;123(2):218-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of activin A on tumor necrosis factor-alpha/intercellular adhesion molecule-1 pathway in endometrial stromal cells.
  • OBJECTIVE[S]: Activin A and inhibin A are growth factors expressed by human endometrium involved in the control of endometrial functions.
  • In the present study we investigated the effects of activin A and inhibin A in modulating the tumor necrosis factor (TNF)-alpha/intercellular adhesion molecule (ICAM)-1 system in cultured human endometrial stromal cells.
  • STUDY DESIGN: Endometrial samples were obtained from 34 reproductive age women undergoing laparoscopy for benign ovarian cysts or infertility.
  • Endometrial stromal cells were cultured and soluble ICAM-1 and TNF-alpha were measured in cell-free supernatants following treatment with or without activin A or inhibin A.
  • Cell surface ICAM-1 was assayed by flow cytometry by staining endometrial cells with specific monoclonal antibodies.
  • RESULTS: Activin A and inhibin A did not influence either the expression of cell surface ICAM-1 or soluble ICAM-1 shedding by cultured endometrial cells.
  • CONCLUSIONS: Since TNF-alpha modulates several endometrial processes such as menstruation, proliferation, apoptosis, implantation and decidualization, an effect of activin A in the physiological control of endometrium is further supported by the present data.
  • [MeSH-major] Activins / pharmacology. Endometrium / drug effects. Immunologic Factors / pharmacology. Inhibin-beta Subunits / pharmacology. Intercellular Adhesion Molecule-1 / metabolism. Tumor Necrosis Factor-alpha / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15893868.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Immunologic Factors; 0 / Interleukin-1; 0 / Tumor Necrosis Factor-alpha; 0 / activin A; 0 / inhibin A; 104625-48-1 / Activins; 126547-89-5 / Intercellular Adhesion Molecule-1; 57285-09-3 / Inhibins; 93443-12-0 / Inhibin-beta Subunits
  •  go-up   go-down


35. Kefeli M, Gonullu G, Can B, Malatyalioglu E, Kandemir B: Metastasis of adenocarcinoma of the gall bladder to an endometrial polyp detected by endometrial curettage: case report and review of the literature. Int J Gynecol Pathol; 2009 Jul;28(4):343-6
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of adenocarcinoma of the gall bladder to an endometrial polyp detected by endometrial curettage: case report and review of the literature.
  • SUMMARY: Polyps are the most common benign lesions in the endometrium.
  • Metastasis to the endometrial polyp from a distant primary tumor is rare.
  • Breast carcinoma is the most frequent extragenital cancer that metastasizes to the endometrial polyp.
  • We report the case of a 63-year-old with metastatic gall bladder adenocarcinoma involving endometrial polyps detected by endometrial curetting.
  • After this diagnosis, bone metastases were detected during radiologic screening.
  • Gastrointestinal tumor metastasis to an endometrial polyp is a very rare event, but if a patient with a known primary extragenital tumor has abnormal vaginal bleeding, the possibility of metastasis should be included in the differential diagnosis.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / secondary. Gallbladder Neoplasms / pathology. Polyps / pathology
  • [MeSH-minor] Aged. Dilatation and Curettage. Female. Humans. Immunohistochemistry. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19483630.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


36. Hachisuga T, Emoto M, Kawarabayashi T, Kamihara Y, Nabeshima K: Endometrial cytologic findings in tamoxifen-treated breast cancer patients. Acta Cytol; 2009 Jan-Feb;53(1):24-8
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial cytologic findings in tamoxifen-treated breast cancer patients.
  • OBJECTIVE: To describe the endometrial cytologic findings in tamoxifen (TAM)-treated patients and evaluate the clinical significance of these findings.
  • STUDY DESIGN: A total of 1,739 endometrial cytologic samples were obtained from 203 breast cancer patients with TAM treatment using an endocyte device.
  • Histologic examinations were recommended for the 23 endometrial cytologic samples (18 initial and 5 follow-up endometrial cytologic samples).
  • RESULTS: A large nuclear dimension and anisokaryosis of the endometrial glandular cells were found in the 23 endometrial cytologic samples.
  • All patients were amenorrheic and postmenopausal except for 3 premenopausal women with endometrial cancer.
  • The subsequent histologic examinations showed 3 atrophic endometria, 3 cystic atrophies, 11 endometrial polyps and 6 endometrial cancers.
  • The tumor diathesis and atypical features of cell aggregates, such as a loss of polarity and severe piling up of nuclei, were seen in the cytologic samples of the endometrial cancers but were not found in those with benign conditions.
  • CONCLUSION: A large nuclear dimension and anisokaryosis of the glandular cells were sometimes found in endometrial cytologic samples from the TAM-treated patients.
  • [MeSH-major] Breast Neoplasms / drug therapy. Endometrium / pathology. Tamoxifen / therapeutic use. Uterine Diseases / diagnosis


37. Ahn HJ, Bae J, Lee S, Ko JE, Yoon S, Kim SJ, Sakuragi N: Differential expression of clusterin according to histological type of endometrial carcinoma. Gynecol Oncol; 2008 Aug;110(2):222-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of clusterin according to histological type of endometrial carcinoma.
  • Endometrial carcinoma is divided into endometrioid and papillary serous type carcinoma according to the histological characteristics and regarding to the unopposed estrogenic stimulation.
  • In this study, we investigated the expression profiles of clusterin according to the histological types and the effect of estrogen stimulation on its expression in endometrial carcinoma.
  • METHOD: Clusterin expression in endometrial carcinoma tissues was examined by RT-PCR, Western blot analysis, and immunohistochemistry.
  • The mRNA and protein expressions of clusterin in endometrioid carcinoma were higher than in benign endometrium (p=0.002).
  • CONCLUSIONS: These data suggest that clusterin expression is related to endometrioid carcinoma of endometrium, in which estrogen is involved in the regulatory network of clusterin.
  • [MeSH-major] Clusterin / biosynthesis. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Estradiol / pharmacology. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Paraffin Embedding. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Stimulation, Chemical

  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18514801.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLU protein, human; 0 / Clusterin; 0 / RNA, Messenger; 4TI98Z838E / Estradiol
  •  go-up   go-down


38. Nordlander C, Behboudi A, Levan G, Levan KK: Allelic imbalance on chromosome 10 in rat endometrial adenocarcinomas. Cancer Genet Cytogenet; 2005 Jan 15;156(2):158-66

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allelic imbalance on chromosome 10 in rat endometrial adenocarcinomas.
  • Earlier work using comparative genome hybridization (CGH) has shown that rat chromosome 10 (RNO10) is frequently involved in cytogenetic aberrations in BDII rat endometrial adenocarcinomas (EAC).
  • The occurrence of RNO10 aberrations was further analyzed in DNA from primary tumor material from 42 EACs and 3 benign endometrial tumors using allelotyping of microsatellite markers.
  • Based on these findings we believe that genes with relevance to EAC tumor development are situated in each of these chromosome regions.
  • [MeSH-major] Adenocarcinoma / genetics. Allelic Imbalance / genetics. Endometrial Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15642397.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Genetic Markers
  •  go-up   go-down


39. Djurdjevic S, Stojanovic S, Kopitovic V, Hadnadjev D, Basta-Nikolic M: Diagnostic value of endosonography scoring systems in the detection of ovarian and endometrial carcinoma. J BUON; 2009 Jan-Mar;14(1):97-102
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of endosonography scoring systems in the detection of ovarian and endometrial carcinoma.
  • PURPOSE: To evaluate the diagnostic significance of sonographic scoring systems in the diagnosis of ovarian and endometrial carcinoma.
  • PATIENTS AND METHODS: 357 women with different malignant and benign diseases of the ovary and uterus were divided into 4 groups according to histopathological findings: group A: ovarian carcinoma (n=71); group B: benign ovarian tumors (n=106); group C: endometrial carcinoma (n=60); and group D: benign endometrial diseases in menopause (hyperplasia, polyps, submucosal myoma; n=120).
  • Women were examined using 7 MHz endovaginal probe and were evaluated using 2 different sonographic scoring systems, separately for ovarian and for endometrial carcinoma.
  • Particular morphological characteristics of ovarian carcinoma (tumor size, echo-characterization: solid-cystic, presence of septum, characteristics of tumor capsule and presence of ascites) were evaluated with points 0-2 (total score: 0-10).
  • For endometrial carcinoma we used a clinico-sonographic scoring system, which included evaluation of the endometrial thickness, isthmus-fundus diameter of uterus, number of years in menopause and the presence of risk factors, using scores 0-2 (total score: 0-8).
  • Using both scoring systems, a total score of 6 points had the highest diagnostic reliability in both ovarian (sensitivity 87.3%, specificity 97.5%, test accuracy 91.6%) and endometrial carcinoma (sensitivity 80%, specificity 91.5%, test accuracy 90.9%).
  • CONCLUSION: A total score of 6 and more points presents the gold standard according to which it is possible to diagnose with high accuracy the existence of ovarian and endometrial carcinoma.
  • [MeSH-major] Carcinoma / ultrasonography. Endometrial Neoplasms / ultrasonography. Endosonography. Ovarian Neoplasms / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19373954.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


40. Dietz NK, Rehn M, Thanner F, Dietl J: [Diagnostic and preoperative staging of endometrial carcinoma with transvaginal sonography--a review]. Zentralbl Gynakol; 2006 Oct;128(5):246-54
MedlinePlus Health Information. consumer health - Ultrasound.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic and preoperative staging of endometrial carcinoma with transvaginal sonography--a review].
  • Endometrial carcinoma is the most common malignant tumor of the female genital tract.
  • Endometrial thickness (double layer) is measured by transvaginal sonography.
  • The cut-off value in patients with postmenopausal bleeding is still controversial, although in patients with endometrial thickness below 4 mm (or 5 mm respectively), malignancy can be excluded with high probability.
  • If the endometrium measures more than 4 mm (or more than 5 mm respectively) or the patient presents with continuous bleeding, hysteroscopy and curettage should be performed in order to obtain histologic diagnosis.
  • Sonographic findings like structure and demarcation of the endometrium increase diagnostic specificity only when combined with the measurement of endometrial thickness.
  • Measuring the fluid within the uterine cavity does not seem to be useful in differentiating malignant from benign disorders.
  • The extent of surgery depends on the preoperative estimation of the tumor stage which is particularly important for elder patients with increased morbidity.
  • This article on transvaginal ultrasound reviews current data on the method's capacity to identify endometrial cancer and to diagnose the depth of invasion.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Neoplasm Staging / methods. Ultrasonography / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001559.001).
  • [ISSN] 0044-4197
  • [Journal-full-title] Zentralblatt für Gynäkologie
  • [ISO-abbreviation] Zentralbl Gynakol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 93
  •  go-up   go-down


41. Kimmich T, Brüning A, Käufl SD, Makovitzky J, Kuhn C, Jeschke U, Friese K, Mylonas I: Inhibin/activin-betaC and -betaE subunits in the Ishikawa human endometrial adenocarcinoma cell line. Arch Gynecol Obstet; 2010 Aug;282(2):185-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibin/activin-betaC and -betaE subunits in the Ishikawa human endometrial adenocarcinoma cell line.
  • However, only limited data on the expression of these novel inhibin subunits in normal human endometrial tissue and endometrial adenocarcinoma cell lines exist.
  • MATERIALS AND METHODS: Samples of proliferative and secretory human endometrium were obtained from five premenopausal, non-pregnant patients undergoing gynecological surgery for benign diseases.
  • Normal endometrial tissue and Ishikawa endometrial adenocarcinoma cell lines were analyzed by immunohistochemistry, immunofluorescence and RT-PCR.
  • RESULTS: Expression of the inhibin betaC and betaE subunits could be demonstrated at the protein level by means of immunohistochemical evaluation and at the transcriptional level by establishing a betaC- and betaE-specific RT-PCR analysis in normal human endometrial tissue and the parental Ishikawa cell line.
  • DISCUSSION: Here, we show for the first time that the novel inhibin/activin-betaC and -betaE subunits are expressed in normal human endometrium and the estrogen receptor positive human endometrial carcinoma cell line Ishikawa using RT-PCR and immunohistochemical detection methods.
  • Interestingly, the Ishikawa minus cell line (lacking estrogen receptor expression) demonstrated no to minimal expression of the betaC subunit as observed with immunofluorescence and RT-PCR, suggesting a possible hormone- dependency of this subunit in human endometrial cancer cells.
  • Moreover, because the Ishikawa cell line minus is thought to be a more malignant endometrial cell line than its estrogen receptor positive counterpart, inhibin-betaC subunit might be substantially involved in the pathogenesis and malignant transformation in human endometrium.
  • [MeSH-major] Adenocarcinoma / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Inhibin-beta Subunits / biosynthesis
  • [MeSH-minor] Cell Dedifferentiation. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Receptors, Estrogen / analysis. Receptors, Estrogen / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20012305.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / INHBC protein, human; 0 / INHBE protein, human; 0 / Receptors, Estrogen; 93443-12-0 / Inhibin-beta Subunits
  •  go-up   go-down


42. Bellone S, Watts K, Cane' S, Palmieri M, Cannon MJ, Burnett A, Roman JJ, Pecorelli S, Santin AD: High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecol Oncol; 2005 Jul;98(1):92-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer.
  • PURPOSE: To evaluate and compare autocrine expression and production of interleukin-6 (IL-6), a pleiotropic cytokine involved in the resistance to cytotoxic agents and inhibition of anti-tumor immune function in endometrial carcinoma in vitro as well as in vivo.
  • PATIENTS AND METHODS: IL-6 gene expression levels were evaluated in twenty-four primary endometrial tumors including 14 endometrioid carcinomas (EC) and 10 uterine serous papillary carcinoma (USPC) as well as in normal control endometrial cells (NEC) by real-time PCR.
  • Secretion of IL-6 protein by 6 primary endometrial tumor cultures including USPC and EC was measured using a sensitive enzyme-linked immunosorbent assay (ELISA) in vitro.
  • Finally, IL-6 concentration in 71 serum samples including 20 apparently healthy women, 19 women with benign abdominal diseases, 19 women with primary EC, and 13 USPC patients was studied.
  • IL-6 serum concentrations between normal healthy females (range 0.01-21.23 pg/ml; mean 3.1 pg/ml) and benign disease patients (range 0.01-95.77 pg/ml; mean 13.07 pg/ml) were not statistically different.
  • [MeSH-major] Cystadenocarcinoma, Papillary / blood. Endometrial Neoplasms / blood. Interleukin-6 / blood
  • [MeSH-minor] Adult. Drug Resistance, Neoplasm. Female. Humans. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15904949.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-6
  •  go-up   go-down


43. Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, Jiang Z: The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol; 2008 Feb;32(2):304-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
  • Insulin-like growth factor II mRNA-binding protein 3 (IMP3) is an oncofetal protein highly expressed in fetal tissue and malignant tumors but rarely found in adult benign tissues.
  • The aim of this study is to determine the expression of IMP3 in benign endometrium, endometrial cancer, and its precursor lesions, trying to see whether IMP3 has any diagnostic usage.
  • Two hundred ninety-eight endometrial samples were examined for IMP3 expression by immunohistochemistry.
  • These included benign endometrium (n=68), atypical hyperplasia or endometrial intraepithelial neoplasia (n=35), endometrial glandular dysplasia (n=21), endometrial intraepithelial carcinoma (n=18), endometrioid carcinoma (n=70), mucinous carcinoma (n=8), serous carcinoma (n=51), clear cell carcinoma (n=12), and other malignancies (n=15).
  • Maturational patterns in the 68 benign endometrial samples included atrophic (n=12), proliferative (n=18), secretory (n=14), menstrual (n=8), and gestational (n=16).
  • Most of the carcinomas were histologically pure; where mixed, the second component constituted <10% of the total tumor volume.
  • Among the malignant cases, IMP3 expression was predominantly found in endometrial serous carcinoma and its putative precursor lesions, with 3 (14%) of 21 endometrial glandular dysplasia, 16 (89%) of 18 serous endometrial intraepithelial carcinoma, and 48 (94%) of 51 serous carcinomas (P<0.001).
  • In contrast, the frequency of IMP3 expression was significantly lesser in nonserous malignancies with 0 (0%) of 35, 5 (7%) of 70, 0 (0%) of 8, 3 (25%) of 12, and 5 (33%) of 15 positive expression rates in atypical hyperplasia or endometrial intraepithelial neoplasia, endometrioid, mucinous, clear cell carcinomas, and other malignancies, respectively.
  • Among the benign endometrial samples, decidualized endometrial stroma showed 100% positivity for IMP3.
  • We conclude that expression of IMP3, a newly identified cytoplasmic marker, is closely associated with type II endometrial cancer.
  • It seems that IMP3 expression is associated with an aggressive histologic phenotype among endometrial neoplastic lesions.
  • Strong and diffuse IMP3 expression is highly sensitive for endometrial serous and clear cell carcinomas including their putative precursor lesions.
  • Therefore, IMP3 may be a useful diagnostic marker in the assessment of endometrial cancers and their precursor lesions, particularly when the amount of available tissue material is limited and a concern of type II cancer arises.
  • High frequency of IMP3 expression is present in decidualized endometrial stroma of gestational endometrium and chorionic villi in early pregnancy.
  • Although the significance of the latter finding remains unclear, the differential diagnosis between decidual changes and endometrial serous carcinoma is rarely problematic.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cystadenocarcinoma, Serous / metabolism. Endometrial Neoplasms / metabolism. Neoplasm Proteins / metabolism. RNA-Binding Proteins / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cytoplasm / metabolism. Cytoplasm / pathology. Endometrium / metabolism. Endometrium / pathology. Female. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Precancerous Conditions / metabolism. Precancerous Conditions / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18223334.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA23074
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins
  •  go-up   go-down


44. Onuma K, Dabbs DJ, Bhargava R: Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium. Int J Gynecol Pathol; 2008 Jul;27(3):418-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium.
  • To investigate the potential use of MGB in gynecologic pathology practice, we tested MGB expression by immunohistochemistry on 47 endocervical adenocarcinomas (whole tissue sections of 13 invasive and 35 in situ) and 55 endometrial carcinomas (39 endometrioid and 16 nonendometrioid represented on a single tissue microarray).
  • Nonneoplastic endocervical and endometrial tissues were also evaluated for MGB expression.
  • MGB expression was detected in thirty (77%) of 39 of endometrioid endometrial adenocarcinomas compared with 4 (31%) of 13 endocervical adenocarcinomas.
  • MGB was mostly negative in nonendometrioid endometrial carcinoma (negative in 14 [88%] of 16).
  • Endocervical adenocarcinoma in situ (AIS) showed either weak (predominantly) or moderate (occasionally) expression in about 40% of the cases in comparison with strong positivity in benign endocervical glandular epithelium.
  • Reduction of MGB staining was seen in transition from benign epithelium to AIS.
  • These results confirm that MGB is not specific for breast carcinoma, but is also variably expressed in nonneoplastic and neoplastic endocervical and endometrial tissues.
  • Frequent MGB expression in endometrioid endometrial adenocarcinoma is significantly different from nonendometrioid carcinoma.
  • Hormone receptor status is not associated with MGB expression in endometrial carcinomas.
  • Most endocervical adenocarcinomas are negative for MGB, in contrast to mostly positive endometrioid endometrial adenocarcinomas, however, MGB expression alone is not specific enough to distinguish these 2 tumor types.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Carcinoma in Situ / metabolism. Neoplasm Proteins / biosynthesis. Uterine Neoplasms / metabolism. Uteroglobin / biosynthesis. Uterus / metabolism
  • [MeSH-minor] Cervix Uteri / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Female. Humans. Immunohistochemistry. Mammaglobin A. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580321.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


45. Dowdy SC, Mariani A, Reinholz MM, Keeney GL, Spelsberg TC, Podratz KC, Janknecht R: Overexpression of the TGF-beta antagonist Smad7 in endometrial cancer. Gynecol Oncol; 2005 Feb;96(2):368-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of the TGF-beta antagonist Smad7 in endometrial cancer.
  • OBJECTIVE: We have shown that HER2/Neu may activate the Smad7 promoter in endometrial, ovarian, and breast cancer cell lines.
  • Elevated Smad7 levels could then antagonize the TGF-beta pathway, leading to a reduction in tumor surveillance and potential cancer formation.
  • Our aim was to determine if Smad7 was in fact overexpressed in endometrial cancers and whether Smad7 RNA levels correlated with tumor grade or clinical endpoints.
  • METHODS: Snap-frozen endometrial cancer specimens from 16 patients with grade 1 disease and 23 patients with grade 3 disease were obtained.
  • Additionally, the endometrium from 18 patients who underwent hysterectomy for benign indications was collected as a control.
  • CONCLUSION: Smad7 appears to be upregulated in endometrial cancers compared to normal endometrium.
  • Given that many endometrial cancers have been shown to be TGF-beta-unresponsive, Smad7 should be investigated as a potential target to restore TGF-beta responsiveness and limit tumor growth.
  • [MeSH-major] DNA-Binding Proteins / biosynthesis. Endometrial Neoplasms / metabolism. Trans-Activators / biosynthesis. Transforming Growth Factor beta / antagonists & inhibitors
  • [MeSH-minor] Cytoskeletal Proteins / biosynthesis. Female. Gene Expression. Humans. Middle Aged. Phosphorylation. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Receptor, ErbB-2 / biosynthesis. Smad2 Protein. Smad3 Protein. Smad7 Protein. beta Catenin

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15661223.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA085257; United States / NCI NIH HHS / CA / CA 085257
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / DNA-Binding Proteins; 0 / RNA, Neoplasm; 0 / SMAD2 protein, human; 0 / SMAD3 protein, human; 0 / SMAD7 protein, human; 0 / Smad2 Protein; 0 / Smad3 Protein; 0 / Smad7 Protein; 0 / Trans-Activators; 0 / Transforming Growth Factor beta; 0 / beta Catenin; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


46. Li J, Dowdy S, Tipton T, Podratz K, Lu WG, Xie X, Jiang SW: HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn; 2009 Sep;9(6):555-66
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HE4 as a biomarker for ovarian and endometrial cancer management.
  • Ovarian and endometrial cancer will be diagnosed in over 63,000 women in 2009, resulting in 22,000 deaths in the USA.
  • Thus, a serum- screening test using a biomarker or panel of biomarkers would be useful to aid in cancer diagnosis, detection of recurrence and as a means to monitor response to therapy.
  • Preliminary data show that HE4 may have more potential than cancer antigen 125 in discriminating benign from cancerous ovarian masses, and has the strongest correlation with endometrial cancer of all markers tested to date.
  • Utilizing risk stratification, a panel of biomarkers including HE4 may ultimately be useful for detecting ovarian and endometrial cancer at an early stage in patients at high risk.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2006 Jun;19(6):847-53 [16607372.001]
  • [Cites] Cancer. 2007 Apr 15;109(8):1513-22 [17354232.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):813-21 [17765190.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4159-61 [17698803.001]
  • [Cites] Gynecol Oncol. 2007 Oct;107(1):58-65 [17659325.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):402-8 [18061248.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2647-55 [18451228.001]
  • [Cites] Adv Exp Med Biol. 2008;622:15-21 [18546615.001]
  • [Cites] Gene. 1999 Oct 1;238(2):375-85 [10570965.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Mol Graph Model. 1999 Apr;17(2):106-13, 134-6 [10680116.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):699-708 [10793106.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5007-11 [11016619.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] Gynecol Oncol. 2000 Dec;79(3):444-50 [11104617.001]
  • [Cites] Eur J Surg Oncol. 2008 Jul;34(7):795-9 [17845837.001]
  • [Cites] Gynecol Oncol. 2008 Aug;110(2):196-201 [18495222.001]
  • [Cites] Gynecol Oncol. 2008 Sep;110(3):374-82 [18584856.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2480-7 [18768519.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):40-6 [18851871.001]
  • [Cites] Zhonghua Fu Chan Ke Za Zhi. 2008 Dec;43(12):931-6 [19134334.001]
  • [Cites] Cancer. 2009 Feb 15;115(4):812-22 [19127552.001]
  • [Cites] Br J Cancer. 2009 Apr 21;100(8):1315-9 [19337252.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):534-40 [11169935.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1176-81 [11158614.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5895-904 [11479231.001]
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1824-30 [11747321.001]
  • [Cites] Gynecol Oncol. 2002 Jan;84(1):36-42 [11748973.001]
  • [Cites] Oncogene. 2002 Apr 18;21(17):2768-73 [11965550.001]
  • [Cites] J Endocrinol. 2002 May;173(2):219-38 [12010630.001]
  • [Cites] Recent Prog Horm Res. 2002;57:435-55 [12017556.001]
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):28-33 [12079296.001]
  • [Cites] Int J Gynecol Cancer. 2002 Jul-Aug;12(4):372-5 [12144685.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1765-8 [12168866.001]
  • [Cites] Biochem J. 2002 Nov 15;368(Pt 1):233-42 [12206714.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3695-700 [12839961.001]
  • [Cites] Mol Biol Cell. 2003 Nov;14(11):4376-86 [12960427.001]
  • [Cites] Biomed Pharmacother. 2004 Jan;58(1):24-38 [14739059.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3919-26 [15173101.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):567-71 [15297205.001]
  • [Cites] Eur Cytokine Netw. 2004 Apr-Jun;15(2):99-104 [15319167.001]
  • [Cites] J Clin Invest. 1981 Nov;68(5):1331-7 [7028788.001]
  • [Cites] Am J Clin Pathol. 1983 Jan;79(1):98-104 [6336888.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Int J Gynecol Pathol. 1983;2(3):275-85 [6196309.001]
  • [Cites] Am J Obstet Gynecol. 1984 Apr 15;148(8):1057-8 [6201072.001]
  • [Cites] Obstet Gynecol. 1985 Apr;65(4):568-72 [3982731.001]
  • [Cites] Clin Chim Acta. 1986 Mar 16;155(2):163-5 [3009058.001]
  • [Cites] Am J Obstet Gynecol. 1986 Nov;155(5):1097-102 [3465243.001]
  • [Cites] Gynecol Oncol. 1988 Jul;30(3):307-12 [3164697.001]
  • [Cites] Br J Obstet Gynaecol. 1989 Dec;96(12):1395-9 [2620051.001]
  • [Cites] Eur J Cancer Clin Oncol. 1989 Dec;25(12):1917-25 [2698807.001]
  • [Cites] Int J Androl. 1990 Apr;13(2):155-67 [1693137.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):14791-5 [2394696.001]
  • [Cites] Acta Obstet Gynecol Scand. 1990;69(5):423-9 [2270768.001]
  • [Cites] Biol Reprod. 1991 Aug;45(2):350-7 [1686187.001]
  • [Cites] Am J Obstet Gynecol. 1992 Nov;167(5):1379-81 [1442994.001]
  • [Cites] Obstet Gynecol. 1995 Aug;86(2):259-64 [7617357.001]
  • [Cites] Cancer Treat Rev. 1995 May;21(3):215-45 [7656266.001]
  • [Cites] Cancer Res. 1995 Dec 15;55(24):6172-80 [8521410.001]
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):141-6 [8995563.001]
  • [Cites] Obstet Gynecol. 1997 Sep;90(3):441-7 [9277659.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Dec;20(4):320-8 [9408747.001]
  • [Cites] J Endocrinol. 1998 Jul;158(1):137-44 [9713335.001]
  • [Cites] Curr Opin Oncol. 1998 Sep;10(5):439-46 [9800115.001]
  • [Cites] Gynecol Oncol. 1999 Jan;72(1):32-7 [9889026.001]
  • [Cites] Biochem J. 1999 Jun 15;340 ( Pt 3):569-77 [10359639.001]
  • [Cites] Ann N Y Acad Sci. 2004 Dec;1028:380-9 [15650263.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2162-9 [15781627.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 29;333(2):383-9 [15950183.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6422-30 [16166416.001]
  • [Cites] J Reprod Med. 2005 Aug;50(8):585-90 [16220763.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):447-61 [16126262.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):45-51 [16382112.001]
  • [Cites] Cancer. 2006 Feb 1;106(3):589-98 [16369985.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 1;98(3):172-80 [16449677.001]
  • [Cites] Lancet Oncol. 2006 Feb;7(2):167-74 [16455481.001]
  • [Cites] Gynecol Oncol. 2006 Mar;100(3):561-4 [16271748.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:11-7 [16515561.001]
  • (PMID = 19732003.001).
  • [ISSN] 1744-8352
  • [Journal-full-title] Expert review of molecular diagnostics
  • [ISO-abbreviation] Expert Rev. Mol. Diagn.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA098258; United States / NICHD NIH HHS / HD / R01 HD041577; United States / NICHD NIH HHS / HD / R01 HD041577-06; United States / NICHD NIH HHS / HD / R01 HD 41577
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / beta-Defensins
  • [Number-of-references] 80
  • [Other-IDs] NLM/ NIHMS145815; NLM/ PMC3273415
  •  go-up   go-down


47. Folkins AK, Nevadunsky NS, Saleemuddin A, Jarboe EA, Muto MG, Feltmate CM, Crum CP, Hirsch MS: Evaluation of vascular space involvement in endometrial adenocarcinomas: laparoscopic vs abdominal hysterectomies. Mod Pathol; 2010 Aug;23(8):1073-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of vascular space involvement in endometrial adenocarcinomas: laparoscopic vs abdominal hysterectomies.
  • Recent reports have described 'vascular pseudoinvasion' in total laparoscopic hysterectomies with endometrial carcinoma.
  • Reports from 58 robotically assisted laparoscopic and 39 abdominal hysterectomies with grade 1 or 2 endometrioid endometrial adenocarcinomas were reviewed for stage, depth of invasion, vascular space involvement, uterine weight, and lymph node metastases.
  • In addition, attention was given to possible procedural artifacts, including vertical endomyometrial clefts, and inflammatory debris, benign endometrial glands, and disaggregated tumor cells in vascular spaces.
  • Disaggregated intravascular tumor cells were significantly associated with reported vascular involvement in both procedures (P-values<0.001 and 0.016), most of which were corroborated on review.
  • [MeSH-major] Artifacts. Blood Vessels / pathology. Carcinoma, Endometrioid / blood supply. Endometrial Neoplasms / blood supply. Hysterectomy / methods
  • [MeSH-minor] Female. Humans. Laparoscopy. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Organ Size

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20473276.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Tatebe S, Oka K, Kuraoka S, Yatabe Y: Benign metastasizing leiomyoma of the lung: potential role of low-grade malignancy. Thorac Cardiovasc Surg; 2009 Apr;57(3):180-3
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign metastasizing leiomyoma of the lung: potential role of low-grade malignancy.
  • One patient was diagnosed as having a benign metastasizing leiomyoma (BML), while the other patient simultaneously developed a left pelvic tumor and multiple lung tumors, both of which were finally diagnosed as low-grade endometrial stromal sarcomas (ESSs).
  • The metastatic potential of BML is not completely understood, but previously reported cases of BML may include low-grade ESS, which may play a significant role in the metastasis of benign uterine tumors.
  • [MeSH-major] Endometrial Neoplasms / pathology. Leiomyomatosis / pathology. Lung Neoplasms / secondary. Pelvic Neoplasms / pathology. Sarcoma, Endometrial Stromal / secondary. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19330762.001).
  • [ISSN] 0171-6425
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


49. Li C, Zota V, Woda BA, Rock KL, Fraire AE, Jiang Z, Lu D, Xu B, Dresser K, Lutman CV, Fischer AH: Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations. Mod Pathol; 2007 Dec;20(12):1263-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations.
  • To investigate the diagnostic and clinicopathologic significance of this protein in endometrial carcinomas, we evaluated immunohistochemical expression of IMP3 in the two most common forms of endometrial malignancies, endometrioid adenocarcinoma and serous carcinoma.
  • We selected 167 endometrial adenocarcinoma cases including 122 cases of endometrioid adenocarcinoma and 45 cases of serous carcinoma.
  • Twenty samples of benign endometrium obtained from 20 patients with nonmalignant uterine lesions were used as controls.
  • Positive immunohistochemical stain for IMP3 was identified in all serous carcinoma cases, among which, 39 (86%) and 3 (7%) cases showed IMP3 immunoreactivity in >50%, and 21-50, or 6-20% of tumor cells, respectively.
  • Thirty (25%), 20 (16%), 10 (8%), and 8 (7%) cases of endometrioid adenocarcinoma demonstrated positive immunoreactivity for IMP3 in 1-5, 6-20, 21-50, and >50% of the tumor cells.
  • To compare p53 with IMP3 expressions, we found that 35 (78%) of the serous carcinoma cases showed strong p53 immunohistochemical activity in >50% of the tumor cell nuclei.
  • In contrast, 11 of 112 (10%) endometrioid adenocarcinoma cases demonstrated strong p53 positivity in >50% of the tumor cell nuclei.
  • Expression of IMP3 and p53 may be helpful biomarkers in the distinction of endometrial serous carcinoma from endometrioid adenocarcinoma.
  • In addition, expression of IMP3 in endometrioid adenocarcinoma correlates with higher nuclear and architecture grades of the tumor (P=0.0000 and P=0.0002, respectively).
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / metabolism. Cystadenocarcinoma, Serous / metabolism. Endometrial Neoplasms / metabolism. Neoplasm Proteins / biosynthesis. RNA-Binding Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / biosynthesis. Diagnosis, Differential. Female. Gene Expression. Humans. Immunohistochemistry. Middle Aged. Tumor Suppressor Protein p53 / biosynthesis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885673.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins; 0 / Tumor Suppressor Protein p53; 0 / oncofetal antigens
  •  go-up   go-down


50. Friel AM, Zhang L, Curley MD, Therrien VA, Sergent PA, Belden SE, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Rueda BR: Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells. Reprod Biol Endocrinol; 2010;8:147
Hazardous Substances Data Bank. AZACITIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells.
  • BACKGROUND: Recent data provide significant evidence to support the hypothesis that there are sub-populations of cells within solid tumors that have an increased tumor initiating potential relative to the total tumor population.
  • CD133, a cell surface marker expressed on primitive cells of neural, hematopoietic, endothelial and epithelial lineages has been identified as a marker for tumor initiating cells in solid tumors of the brain, colon, pancreas, ovary and endometrium.
  • Our objectives were to assess the relative level of CD133 expressing cells in primary human endometrial tumors, confirm their tumorigenic potential, and determine whether CD133 expression was epigenetically modified.
  • METHODS: We assessed CD133 expression in primary human endometrial tumors by flow cytometry and analyzed the relative tumorigenicity of CD133+ and CD133- cells in an in vivo NOD/SCID mouse model.
  • We further examined CD133 promoter methylation and expression in normal endometrium and malignant tumors.
  • RESULTS: As determined by flow cytometric analysis, the percentage of CD133+ cells in primary human endometrial cancer samples ranged from 5.7% to 27.4%.
  • In addition, we confirmed the tumor initiating potential of CD133+ and CD133- cell fractions in NOD/SCID mice.
  • Interestingly, the percentage of CD133+ cells in human endometrial tumor xenografts, as evidenced by immunofluorescence, increased with serial transplantation although this trend was not consistently detected by flow cytometry.
  • We also determined that the relative levels of CD133 increased in endometrial cancer cell lines following treatment with 5-aza-2'-deoxycytidine suggesting a role for methylation in the regulation of CD133.
  • To support this finding, we demonstrated that regions of the CD133 promoter were hypomethylated in malignant endometrial tissue relative to benign control endometrial tissue.
  • Lastly, we determined that methylation of the CD133 promoter decreases over serial transplantation of an endometrial tumor xenograft.
  • CONCLUSIONS: These findings support the hypotheses that CD133 expression in endometrial cancer may be epigenetically regulated and that cell fractions enriched for CD133+ cells may well contribute to endometrial cancer tumorigenicity, pathology and recurrence.
  • [MeSH-major] Antigens, CD / genetics. Cell Transformation, Neoplastic / pathology. Endometrial Neoplasms / pathology. Epigenomics. Glycoproteins / genetics. Neoplastic Stem Cells / pathology. Peptides / genetics
  • [MeSH-minor] Animals. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Female. Humans. Mice. Mice, Inbred NOD. Mice, SCID. Neoplasm Transplantation

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Res. 2008 Oct;18(10):1037-46 [18679414.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):8094-103 [18829568.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):158-66 [19158483.001]
  • [Cites] Cancer Lett. 2009 Jun 28;279(1):13-21 [19232461.001]
  • [Cites] Biol Reprod. 2009 Jun;80(6):1136-45 [19228591.001]
  • [Cites] Anticancer Res. 2009 Jun;29(6):2235-7 [19528487.001]
  • [Cites] Clin Cancer Res. 2009 Jul 1;15(13):4299-311 [19509143.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] BMC Cancer. 2009;9:221 [19583859.001]
  • [Cites] Cancer Res. 2009 Nov 1;69(21):8241-8 [19843861.001]
  • [Cites] Stem Cells. 2009 Oct;27(10):2405-13 [19658191.001]
  • [Cites] Stem Cells. 2009 Dec;27(12):2875-83 [19816957.001]
  • [Cites] J Biochem. 2010 Sep;148(3):273-80 [20551139.001]
  • [Cites] Hum Pathol. 2010 Nov;41(11):1516-29 [20800872.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):213-23 [14747944.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):295-308 [10757340.001]
  • [Cites] Endocr Relat Cancer. 2000 Dec;7(4):227-42 [11174845.001]
  • [Cites] Breast Cancer Res. 2003;5(1):R1-8 [12559051.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2055-61 [14630820.001]
  • [Cites] Biol Reprod. 2004 Jun;70(6):1738-50 [14766732.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Biol Reprod. 1989 Mar;40(3):681-90 [2758097.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5002-12 [9389720.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5013-21 [9389721.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Stem Cells. 2006 Jun;24(6):1529-38 [16456137.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4783-91 [17028294.001]
  • [Cites] Hum Reprod. 2007 Jan;22(1):45-51 [16923745.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Hum Reprod. 2007 May;22(5):1214-23 [17283036.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):479-85 [17762575.001]
  • [Cites] Cell Cycle. 2008 Jan 15;7(2):242-9 [18256549.001]
  • [Cites] Int J Gynecol Cancer. 2008 May-Jun;18(3):506-14 [17868344.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4311-20 [18519691.001]
  • [Cites] J Mol Med (Berl). 2008 Sep;86(9):1025-32 [18535813.001]
  • [Cites] Oncogene. 2009 Jan 15;28(2):209-18 [18836486.001]
  • (PMID = 21122138.001).
  • [ISSN] 1477-7827
  • [Journal-full-title] Reproductive biology and endocrinology : RB&E
  • [ISO-abbreviation] Reprod. Biol. Endocrinol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA098258; United States / NCI NIH HHS / CA / P50 CA098258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Peptides; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC3027593
  •  go-up   go-down


51. Yi N, Liao QP, Li T, Xiong Y: Novel expression profiles and invasiveness-related biology function of DKK1 in endometrial carcinoma. Oncol Rep; 2009 Jun;21(6):1421-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel expression profiles and invasiveness-related biology function of DKK1 in endometrial carcinoma.
  • In this study, we showed that in benign and malignant endometrium, DKK1 exhibited novel expression profiles and invasiveness-related biology function: DKK1 was expressed in both glandular epithelium and matrix of two kinds of endometrium tissues and mostly distributed in the cytoplasm and epicytes of endometrial carcinoma (EC) Ishikawa cell line.
  • DKK1 expression level in EC was significantly lower than that in benign endometrium.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Intercellular Signaling Peptides and Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Cell Movement. Down-Regulation. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Signal Transduction. beta Catenin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19424619.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / DKK1 protein, human; 0 / Intercellular Signaling Peptides and Proteins; 0 / beta Catenin
  •  go-up   go-down


52. Tamai K, Koyama T, Saga T, Morisawa N, Fujimoto K, Mikami Y, Togashi K: The utility of diffusion-weighted MR imaging for differentiating uterine sarcomas from benign leiomyomas. Eur Radiol; 2008 Apr;18(4):723-30
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The utility of diffusion-weighted MR imaging for differentiating uterine sarcomas from benign leiomyomas.
  • The usefulness of diffusion-weighted (DW) magnetic resonance (MR) imaging for the diagnosis of uterine sarcomas was investigated, as well as whether DW images and quantitative measurement of apparent diffusion coefficient (ADC) values can facilitate differentiating uterine sarcomas from benign leiomyomas.
  • MR images including DW images were obtained in 43 surgically treated patients with 58 myometrial tumors, including seven uterine sarcomas (five leiomyosarcomas and two endometrial stromal sarcomas) and 51 benign leiomyomas (43 ordinary leiomyomas, two cellular leiomyomas and six degenerated leiomyomas).
  • Qualitative analysis of non-enhanced and postcontrast MR images and DW images and quantitative measurement of ADC values were performed for each myometrial tumor.
  • In addition to morphological features on nonenhanced and postcontrast MR sequences, DW imaging and ADC measurement may have a potential ability to differentiate uterine sarcomas from benign leiomyomas.
  • [MeSH-minor] Adult. Aged. Contrast Media. Diagnosis, Differential. Female. Humans. Image Interpretation, Computer-Assisted. Middle Aged

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 1999 Sep;173(3):767-72 [10470920.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Jan;22(1):112-8 [11158896.001]
  • [Cites] Int J Clin Oncol. 2006 Aug;11(4):278-85 [16937301.001]
  • [Cites] Obstet Gynecol. 1986 Mar;67(3):417-24 [3945454.001]
  • [Cites] Int J Gynecol Cancer. 2002 Jul-Aug;12(4):354-61 [12144683.001]
  • [Cites] Radiographics. 1999 Oct;19 Spec No:S131-45 [10517450.001]
  • [Cites] Eur Radiol. 2007 Oct;17(10):2646-55 [17356840.001]
  • [Cites] Radiat Med. 2004 Jul-Aug;22(4):275-82 [15468951.001]
  • [Cites] Eur Radiol. 2007 Jan;17(1):201-4 [16865369.001]
  • [Cites] J Magn Reson Imaging. 2005 Mar;21(3):258-62 [15723379.001]
  • [Cites] Radiology. 1989 May;171(2):531-4 [2704819.001]
  • [Cites] Magn Reson Med. 1999 Jan;41(1):143-7 [10025622.001]
  • [Cites] Abdom Imaging. 2007 Jul-Aug;32(4):481-3 [17431713.001]
  • [Cites] Jpn J Clin Oncol. 2004 Oct;34(10):620-6 [15591461.001]
  • [Cites] Magn Reson Med. 1995 May;33(5):697-712 [7596275.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jan-Feb;29(1):83-6 [15665689.001]
  • [Cites] AJR Am J Roentgenol. 2003 Dec;181(6):1705-9 [14627600.001]
  • [Cites] Radiology. 2005 Jul;236(1):196-203 [15987974.001]
  • [Cites] Eur Radiol. 2007 Jun;17(6):1385-93 [17206421.001]
  • [Cites] Radiology. 2003 Jan;226(1):71-8 [12511671.001]
  • [Cites] AJR Am J Roentgenol. 1992 Sep;159(3):591-9 [1503032.001]
  • [Cites] J Magn Reson Imaging. 1996 Sep-Oct;6(5):833-45 [8890023.001]
  • [Cites] Eur Radiol. 2000;10(5):780-2 [10823633.001]
  • [Cites] Eur Radiol. 2006 Jul;16(7):1468-77 [16557366.001]
  • [Cites] J Magn Reson Imaging. 2004 Jul;20(1):97-104 [15221814.001]
  • [Cites] Eur Radiol. 2005 Jan;15(1):71-8 [15538578.001]
  • [Cites] Magn Reson Med. 2000 Jun;43(6):828-36 [10861877.001]
  • [Cites] Radiology. 1993 Dec;189(3):721-5 [8234695.001]
  • [Cites] Eur Radiol. 2001;11(1):28-33 [11194912.001]
  • [Cites] AJR Am J Roentgenol. 1998 Feb;170(2):397-402 [9456953.001]
  • [Cites] J Magn Reson Imaging. 2004 Dec;20(6):998-1007 [15558559.001]
  • [Cites] J Magn Reson Imaging. 2001 May;13(5):757-60 [11329198.001]
  • [Cites] Radiology. 2006 Apr;239(1):122-30 [16493012.001]
  • [Cites] AJR Am J Roentgenol. 2001 Dec;177(6):1307-11 [11717072.001]
  • [Cites] Eur Radiol. 2007 Oct;17(10):2631-7 [17429643.001]
  • [Cites] Radiology. 2007 May;243(2):570-7 [17400757.001]
  • (PMID = 17929022.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


53. Carlsson J, Helenius G, Karlsson M, Klinga-Levan K: Loss of glutathione peroxidase 3 expression is correlated with epigenetic mechanisms in endometrial adenocarcinoma. Cancer Cell Int; 2010 Nov 24;10:46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of glutathione peroxidase 3 expression is correlated with epigenetic mechanisms in endometrial adenocarcinoma.
  • In a previous microarray study performed by our group, Gpx3 was identified as a potential biomarker for rat endometrial adenocarcinoma (EAC), since the expression was highly downregulated in rat EAC tumors.
  • In addition we have examined the expression of GPX3 and MET in 30 human EACs of different FIGO grades and 20 benign endometrial tissues.
  • We found that the expression of GPX3 was uniformly down regulated in both rat and human EAC, regardless of tumor grade or histopathological subtype, implying that the down-regulation is an early event in EAC.
  • The expression of the Met oncogene was slightly upregulated in EACs that showed loss of expression of Gpx3, but no tumor suppressor activity of Gpx3/GPX3 was detected.
  • Preliminary results also suggest that the production of H2O2 is higher in rat endometrial tumors with down-regulated Gpx3 expression.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Neonate. 1990;57(6):343-8 [2164849.001]
  • [Cites] Cancer Metastasis Rev. 2008 Mar;27(1):85-94 [18175071.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1427-31 [12424112.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):649-62 [15188130.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4218-27 [15899813.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):794-8 [1846317.001]
  • [Cites] Z Versuchstierkd. 1987;30(5-6):209-16 [3445711.001]
  • [Cites] Cancer Cell Int. 2009;9:12 [19426485.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11715-20 [9751731.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1472-81 [17245700.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25 [14685170.001]
  • [Cites] Oncogene. 1999 Apr 8;18(14):2343-50 [10327054.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2081-8 [17332337.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jun;127(2):118-27 [11425450.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 24;91(11):4731-5 [8197126.001]
  • [Cites] J Natl Cancer Inst. 1987 Jun;78(6):1245-51 [3473261.001]
  • [Cites] Curr Probl Cancer. 1997 Mar-Apr;21(2):65-127 [9128804.001]
  • [Cites] Science. 1991 Feb 15;251(4995):802-4 [1846706.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8043-50 [17804715.001]
  • [Cites] J Cell Biol. 2001 May 28;153(5):1023-34 [11381087.001]
  • [Cites] Oncol Rep. 2008 Dec;20(6):1299-303 [19020706.001]
  • [Cites] Eur J Cancer. 2009 May;45(7):1282-93 [19195878.001]
  • [Cites] Cancer Detect Prev. 1987;10(3-4):237-46 [3568022.001]
  • [Cites] Int J Oncol. 2010 Feb;36(2):405-14 [20043075.001]
  • [Cites] Verh Dtsch Ges Pathol. 1997;81:228-32 [9474874.001]
  • [Cites] Neoplasia. 2005 Sep;7(9):854-61 [16229808.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):701-6 [9012848.001]
  • [Cites] Endocr Relat Cancer. 2003 Mar;10(1):23-42 [12653669.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4742-9 [16651427.001]
  • (PMID = 21106063.001).
  • [ISSN] 1475-2867
  • [Journal-full-title] Cancer cell international
  • [ISO-abbreviation] Cancer Cell Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3014921
  •  go-up   go-down


54. Ben-Nagi J, Miell J, Mavrelos D, Naftalin J, Lee C, Jurkovic D: Endometrial implantation factors in women with submucous uterine fibroids. Reprod Biomed Online; 2010 Nov;21(5):610-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial implantation factors in women with submucous uterine fibroids.
  • Uterine fibroids are benign tumours, which are associated with subfertility and early pregnancy loss.
  • Premenopausal women with a certain diagnosis of submucous fibroid confirmed on three-dimensional saline infusion sonohysterography were recruited into the study.
  • The control group included women without ultrasonic evidence of any uterine or endometrial pathology.
  • Women with a confirmed diagnosis of submucous fibroids were asked to attend the clinic and have the uterine cavity flushed with a special solution 7days after ovulation.
  • [MeSH-minor] Adult. Female. Humans. Insulin-Like Growth Factor Binding Protein 1 / metabolism. Interleukin-6 / metabolism. Middle Aged. Osteopontin / metabolism. Pregnancy. Prospective Studies. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20880745.001).
  • [ISSN] 1472-6491
  • [Journal-full-title] Reproductive biomedicine online
  • [ISO-abbreviation] Reprod. Biomed. Online
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / Insulin-Like Growth Factor Binding Protein 1; 0 / Interleukin-6; 0 / PAEP protein, human; 0 / Pregnancy Proteins; 0 / Tumor Necrosis Factor-alpha; 106441-73-0 / Osteopontin; 130068-27-8 / Interleukin-10
  •  go-up   go-down


55. Pillay OC, Te Fong LF, Crow JC, Benjamin E, Mould T, Atiomo W, Menon PA, Leonard AJ, Hardiman P: The association between polycystic ovaries and endometrial cancer. Hum Reprod; 2006 Apr;21(4):924-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association between polycystic ovaries and endometrial cancer.
  • BACKGROUND: Women with polycystic ovary syndrome (PCOS) are assumed to be at increased risk of endometrial cancer (EC), albeit of a more differentiated type with better prognosis than in normal women.
  • METHODS: The prevalence of polycystic ovaries (PCO), as a marker of PCOS, was investigated in ovarian sections from 128 women with EC and 83 with benign gynaecological conditions.
  • The expression of the prognostic markers p53, Ki67, Bcl2 and cyclin D1 was also investigated by immunohistochemistry in endometrial tumours from 11 women with PCO and 16 with normal ovaries.
  • RESULTS: Overall, PCO were similarly prevalent in women with EC (8.6%) and benign controls (8.4%); however, in women aged <50 years, PCO were more prevalent in women with EC (62.5 versus 27.3%, P = 0.033).
  • Cyclin D1-expressing endometrial tumours tended to be more prevalent in women with PCO compared to normal ovaries (36.4 versus 6.25%, respectively, P = 0.071).
  • The tendency for cyclin D1-expressing endometrial tumours to be more prevalent in women with PCO challenges the assumption that EC prognosis is improved in women with PCOS.
  • [MeSH-major] Endometrial Neoplasms / complications. Polycystic Ovary Syndrome / complications
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor. Cyclin D1 / metabolism. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Middle Aged. Ovary / pathology. Prognosis. Proto-Oncogene Proteins / metabolism. Risk Factors. Tumor Suppressor Protein p53 / metabolism


56. Krockenberger M, Engel JB, Schmidt M, Kohrenhagen N, Häusler SF, Dombrowski Y, Kapp M, Dietl J, Honig A: Expression of transketolase-like 1 protein (TKTL1) in human endometrial cancer. Anticancer Res; 2010 May;30(5):1653-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of transketolase-like 1 protein (TKTL1) in human endometrial cancer.
  • The metabolic switch from oxidative glycolysis to non-oxidative fermentation of glucose and proteins performed by the tumor cells seems to be associated with TKTL1 and pAkt overexpression.
  • Therefore the aim of the present study was to investigate the expression of TKTL1 and pAkt in human specimens of endometrial cancer as compared to benign endometrium.
  • MATERIALS AND METHODS: Levels of TKTL1, pAkt, and GLUT1 expression were immunhistochemically evaluated on paraffin embedded biopsy material from 10 benign and 41 malignant endometrial tissue samples.
  • TKTL1 mRNA levels in the endometrial cancer cell lines Ishikawa and HEC-1A were evaluated by RT-PCR.
  • RESULTS: Expression of TKTL1, GLUT1 and pAKT was significantly increased in endometrial carcinomas as compared to benign endometrial tissue.
  • In the human endometrial cancer cell lines Ishikawa and HEC-1A, TKTL1 mRNA was clearly detectable.
  • CONCLUSION: The levels of TKTL1, GLUT1 and pAKT expression point to the glycolytic phenotype of malignant endometrial tissue.
  • Given the pronounced TKTL1 expression across all different subtypes of endometrial cancer, this protein could serve as a target for future cancer treatments.
  • [MeSH-major] Endometrial Neoplasms / metabolism. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Transketolase / biosynthesis
  • [MeSH-minor] Aged. Cell Line, Tumor. Female. Glucose / metabolism. Glucose Transporter Type 1 / metabolism. Glycolysis. Humans. Immunohistochemistry / methods. Middle Aged. Oxygen / chemistry. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592357.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / RNA, Messenger; 0 / SLC2A1 protein, human; EC 2.2.1.1 / TKTL1 protein, human; EC 2.2.1.1 / Transketolase; IY9XDZ35W2 / Glucose; S88TT14065 / Oxygen
  •  go-up   go-down


57. Tamai K, Koyama T, Saga T, Kido A, Kataoka M, Umeoka S, Fujii S, Togashi K: MR features of physiologic and benign conditions of the ovary. Eur Radiol; 2006 Dec;16(12):2700-11
MedlinePlus Health Information. consumer health - Ovarian Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR features of physiologic and benign conditions of the ovary.
  • Benign ovarian diseases can also simulate malignancies.
  • Magnetic resonance imaging (MRI) can play an important role in establishing accurate diagnosis.
  • Recognition of clinical settings can help establish diagnosis.
  • In endometrial cysts, MRI usually provides specific diagnosis; however, decidual change during pregnancy should not be confused with secondary neoplasm.
  • Many benign tumors, including teratoma, Brenner tumor, and sex-cord stromal tumor, frequently show characteristic MRI features.
  • Knowledge of MRI features of these conditions is essential in establishing accurate diagnosis and determining appropriate treatment.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Ovarian Diseases / diagnosis. Ovary / anatomy & histology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Radiol. 1999 Oct;72(862):1006-11 [10673954.001]
  • [Cites] J Comput Assist Tomogr. 2000 Jan-Feb;24(1):72-6 [10667663.001]
  • [Cites] J Comput Assist Tomogr. 1999 Jul-Aug;23(4):555-7 [10433285.001]
  • [Cites] J Magn Reson Imaging. 2004 Sep;20(3):451-62 [15332253.001]
  • [Cites] Eur Radiol. 2001;11(7):1151-4 [11471603.001]
  • [Cites] Radiology. 1993 Feb;186(2):489-94 [8421756.001]
  • [Cites] Hum Reprod. 2001 Jun;16(6):1261-3 [11387302.001]
  • [Cites] Obstet Gynecol. 1977 Jul;50(1):120-8 [195239.001]
  • [Cites] Magn Reson Imaging. 1998 Dec;16(10):1147-53 [9858270.001]
  • [Cites] Eur Radiol. 1999;9(7):1335-8 [10460370.001]
  • [Cites] J Clin Ultrasound. 1981 Jul-Aug;9(6):275-80 [6454699.001]
  • [Cites] J Comput Assist Tomogr. 2001 Mar-Apr;25(2):201-6 [11242213.001]
  • [Cites] Radiology. 1991 Jul;180(1):73-8 [2052726.001]
  • [Cites] J Comput Assist Tomogr. 1990 Sep-Oct;14 (5):833-4 [2398172.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):648-50 [14675693.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):223-5 [15262147.001]
  • [Cites] AJR Am J Roentgenol. 2000 Jun;174(6):1559-63 [10845480.001]
  • [Cites] Radiology. 1996 Dec;201(3):751-5 [8939226.001]
  • [Cites] Radiographics. 2004 Oct;24 Suppl 1:S147-66 [15486238.001]
  • [Cites] Radiographics. 2002 Mar-Apr;22(2):283-94 [11896219.001]
  • [Cites] Radiographics. 2004 Nov-Dec;24(6):1575-89 [15537966.001]
  • [Cites] J Thorac Imaging. 2003 Apr;18(2):100-3 [12700485.001]
  • [Cites] AJR Am J Roentgenol. 2000 Aug;175(2):353-8 [10915674.001]
  • [Cites] J Comput Assist Tomogr. 1993 May-Jun;17 (3):477-9 [8491915.001]
  • [Cites] Eur Radiol. 2000;10(12):1954-7 [11305578.001]
  • [Cites] Radiology. 1996 Feb;198(2):397-402 [8596839.001]
  • [Cites] Korean J Radiol. 2005 Jan-Mar;6(1):44-6 [15782020.001]
  • [Cites] J Magn Reson Imaging. 1998 Nov-Dec;8(6):1203-6 [9848729.001]
  • [Cites] Eur Radiol. 2004 May;14 (5):798-804 [14504904.001]
  • [Cites] Radiographics. 2001 Mar-Apr;21(2):475-90 [11259710.001]
  • [Cites] AJR Am J Roentgenol. 2003 May;180(5):1288-90 [12704039.001]
  • [Cites] Radiographics. 2005 Jan-Feb;25(1):69-85 [15653588.001]
  • [Cites] Radiology. 1999 Jan;210(1):209-16 [9885610.001]
  • [Cites] Magn Reson Imaging. 2002 Apr;20(3):301-4 [12117613.001]
  • [Cites] AJR Am J Roentgenol. 1999 Feb;172(2):445-9 [9930800.001]
  • [Cites] AJR Am J Roentgenol. 1994 Sep;163(3):613-6 [8079854.001]
  • [Cites] Hum Reprod. 2002 Sep;17(9):2219-27 [12202405.001]
  • [Cites] Int J Gynecol Pathol. 1984;3(2):153-78 [6490313.001]
  • [Cites] AJR Am J Roentgenol. 2000 Nov;175(5):1423-30 [11044056.001]
  • [Cites] Top Magn Reson Imaging. 2001 Apr;12(2):131-46 [11296805.001]
  • [Cites] Radiology. 1996 Nov;201(2):549-52 [8888256.001]
  • [Cites] Radiol Clin North Am. 2003 Jul;41(4):799-811 [12899493.001]
  • (PMID = 16736136.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 44
  •  go-up   go-down


58. Xiong Y, Xiong YY, Zhou YF: Expression and significance of beta-catenin, Glut-1 and PTEN in proliferative endometrium, endometrial intraepithelial neoplasia and endometrioid adenocarcinoma. Eur J Gynaecol Oncol; 2010;31(2):160-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and significance of beta-catenin, Glut-1 and PTEN in proliferative endometrium, endometrial intraepithelial neoplasia and endometrioid adenocarcinoma.
  • OBJECTIVE: The aim of this study was to explore the potentiality of beta-catenin, Glut-1 and PTEN proteins as markers for a diagnosis of endometrial intraepithelial neoplasia (EIN).
  • DESIGN: Ten proliferative endometrium, 83 endometrial hyperplasia (59 benign hyperplasia, 24 EIN) and 24 endometrioid adenocarcinoma sections were immunostained for beta-catenin, Glut-1 and PTEN protein expression. RESULTS:.
  • (1) Abnormal expression of beta-catenin was detected in 10% of benign hyperplasia, 50% of EIN and 67% of endometriold adenocarcinoma. (2) Overexpression of Glut-1 was present in 58% of EIN and 71% of endometrioid adenocarcinoma. (3) Complete loss of PTEN immunoreactivity was found in 20% of proliferative endometrium, 29% of benign hyperplasia, 38% of EIN and 63% of endometrioid adenocarcinoma.
  • CONCLUSIONS: The abnormal expression of beta-catenin and overexpression of Glut-1 may be useful markers in distinguishing benign hyperplasia from EIN, whereas lack of PTEN expression is not an appropriate marker for a diagnosis of EIN.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Glucose Transporter Type 1 / metabolism. PTEN Phosphohydrolase / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20527231.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / beta Catenin; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


59. DeBernardo RL, Littell RD, Luo H, Duska LR, Oliva E, Kirley SD, Lynch MP, Zukerberg LR, Rueda BR: Defining the extent of cables loss in endometrial cancer subtypes and its effectiveness as an inhibitor of cell proliferation in malignant endometrial cells in vitro and in vivo. Cancer Biol Ther; 2005 Jan;4(1):103-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defining the extent of cables loss in endometrial cancer subtypes and its effectiveness as an inhibitor of cell proliferation in malignant endometrial cells in vitro and in vivo.
  • Loss of Cables expression is associated with a high incidence of endometrial hyperplasia and endometrial adenocarcinoma in humans.
  • The Cables mutant mouse develops endometrial hyperplasia and following exposure to chronic estrogen develops early endometrial adenocarcinoma.
  • (1) loss of Cables expression occurred in high grade endometrioid adenocarcinoma, uterine serous and clear cell carcinoma as observed in endometrial hyperplasia and low grade endometrial adenocarcinoma;.
  • (2) overexpression of Cables inhibited cell proliferation in endometrial cancer (EC) cells in vitro and in vivo; and (3) progesterone could regulate the expression of Cables mRNA.
  • Hyperplastic endometrium and low and high grade endometrioid adenocarcinoma showed loss of Cables expression when compared to benign control secretory endometrium.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Cell Proliferation. Endometrial Neoplasms / genetics. Endometrial Neoplasms / pathology. Gene Expression Profiling
  • [MeSH-minor] Animals. Carrier Proteins. Cyclins. Female. Humans. Mice. Phosphoproteins. Receptors, Progesterone / physiology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15662117.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA98333
  • [Publication-type] Clinical Conference; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CABLES1 protein, human; 0 / Carrier Proteins; 0 / Cyclins; 0 / Phosphoproteins; 0 / Receptors, Progesterone
  •  go-up   go-down


60. Li X, Qi X, Zhou L, Catera D, Rote NS, Potashkin J, Abdul-Karim FW, Gorodeski GI: Decreased expression of P2X7 in endometrial epithelial pre-cancerous and cancer cells. Gynecol Oncol; 2007 Jul;106(1):233-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased expression of P2X7 in endometrial epithelial pre-cancerous and cancer cells.
  • OBJECTIVES: To understand the potential role of P2X(7) as biomarker of endometrial cancer, and the molecular mechanisms by which cancerous epithelial cells maintain low expression of P2X(7).
  • Normal (28), simple or complex hyperplasia (7), complex hyperplasia with atypia (6) and cancer endometrial discarded tissues (40) were obtained from a total of 81 women, ages 25-75.
  • RESULTS: Levels of P2X(7) protein and mRNA were significantly lower in vivo, in tissues of complex hyperplasia with atypia or endometrial adenocarcinoma, than in tissues of normal endometrium, simple hyperplasia or complex hyperplasia tissues (sensitivity and specificity of 89-100%, p<0.0001-0.01).
  • CONCLUSIONS: Tissue levels of P2X(7) protein and mRNA can differentiate effectively and accurately between normal and benign hyperplastic endometrial tissues from pre-cancerous and cancer tissues.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacol Rev. 1998 Sep;50(3):413-92 [9755289.001]
  • [Cites] Br J Pharmacol. 1999 Aug;127(8):1915-21 [10482924.001]
  • [Cites] Endocrinology. 2004 Dec;145(12):5568-79 [15319352.001]
  • [Cites] Endocrinology. 2005 Jan;146(1):164-74 [15459114.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Jun;288(6):C1342-56 [15728711.001]
  • [Cites] Obstet Gynecol. 2005 Aug;106(2):413-25 [16055605.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):388-92 [16051336.001]
  • [Cites] Public Health Nutr. 2005 Oct;8(7):912-9 [16277808.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):812-9 [16400639.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):804-11 [16400640.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):729-31 [16400641.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2006 Apr;20(2):363-77 [16364689.001]
  • [Cites] Hum Reprod. 2006 Apr;21(4):924-9 [16361289.001]
  • [Cites] J Biol Chem. 2006 Jun 23;281(25):17228-37 [16624800.001]
  • [Cites] Am J Epidemiol. 2006 Jul 1;164(1):56-62 [16675538.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1906-13 [17035398.001]
  • [Cites] Cancer. 2000 Oct 15;89(8):1765-72 [11042572.001]
  • [Cites] Gene. 2001 Mar 7;265(1-2):11-23 [11255003.001]
  • [Cites] Curr Opin Cell Biol. 2001 Jun;13(3):320-5 [11343902.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):4590-6 [12464620.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Nov;287(5):C1349-58 [15269006.001]
  • [Cites] Cell. 1982 Nov;31(1):11-24 [6186379.001]
  • [Cites] Differentiation. 1994 Apr;56(1-2):107-18 [7517899.001]
  • (PMID = 17482244.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / R01 AG015955-03; United States / NIA NIH HHS / AG / AG015955-06; United States / NIA NIH HHS / AG / AG015955-05; United States / NIA NIH HHS / AG / AG015955-09; United States / NIA NIH HHS / AG / R01 AG015955-06; United States / NIA NIH HHS / AG / AG015955-04; United States / NIA NIH HHS / AG / R01 AG015955-05; United States / NIA NIH HHS / AG / R01 AG015955-02; United States / NIA NIH HHS / AG / R01 AG015955-07; United States / NIA NIH HHS / AG / AG015955-07; United States / NIA NIH HHS / AG / AG015955-03; United States / NIA NIH HHS / AG / R01 AG015955-01A1; United States / NIA NIH HHS / AG / AG015955-02; United States / NIA NIH HHS / AG / AG15955; United States / NIA NIH HHS / AG / R01 AG015955-04; United States / NIA NIH HHS / AG / R01 AG015955-08; United States / NIA NIH HHS / AG / AG015955-08; United States / NIA NIH HHS / AG / AG015955-01A1; United States / NIA NIH HHS / AG / R01 AG015955; United States / NIA NIH HHS / AG / R01 AG015955-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / P2RX7 protein, human; 0 / RNA, Messenger; 0 / Receptors, Purinergic P2; 0 / Receptors, Purinergic P2X7
  • [Other-IDs] NLM/ NIHMS47290; NLM/ PMC2398694
  •  go-up   go-down


61. Fujii H, Jiang W, Matsumoto T, Miyai K, Sashara K, Ohtsuji N, Hino O: Birt-Hogg-Dubé gene mutations in human endometrial carcinomas with microsatellite instability. J Pathol; 2006 Jul;209(3):328-35
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Birt-Hogg-Dubé gene mutations in human endometrial carcinomas with microsatellite instability.
  • Birt-Hogg-Dubé (BHD) syndrome is a rare form of autosomal dominantly inherited genodermatosis characterized by benign hamartomatous skin lesions named fibrofolliculomas, and an increased risk for developing pulmonary cyst/pneumothorax and various forms of renal cell carcinoma.
  • To test the hypothesis that the BHD gene is also a mutational target in sporadic endometrial carcinoma with microsatellite instability, 139 cases of sporadic endometrial carcinoma were screened for MSI status, and mutations of the poly(C)8 tract in exon 11 as well as other coding exons of the BHD gene.
  • Taken together, these findings show that the BHD gene is a target gene in MSI endometrial carcinoma.
  • [MeSH-major] Endometrial Neoplasms / genetics. Microsatellite Repeats / genetics. Mutation. Neoplastic Syndromes, Hereditary / genetics. Proteins / genetics. Proto-Oncogene Proteins / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adult. Aged. Aged, 80 and over. Base Sequence. Carrier Proteins / genetics. DNA Methylation. DNA-Binding Proteins / genetics. Disease Progression. Female. Humans. Microdissection / methods. Middle Aged. Molecular Sequence Data. Neoplasm Proteins / genetics. Nuclear Proteins / genetics. bcl-2-Associated X Protein / genetics

  • Genetic Alliance. consumer health - Birt-Hogg-Dube Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Pathological Society of Great Britain and Ireland.
  • (PMID = 16691634.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / FLCN protein, human; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Proteins; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Proteins; 0 / bcl-2-Associated X Protein
  •  go-up   go-down


62. Shen SH, Chiou YY, Wang JH, Yen MS, Lee RC, Lai CR, Chang CY: Diffusion-weighted single-shot echo-planar imaging with parallel technique in assessment of endometrial cancer. AJR Am J Roentgenol; 2008 Feb;190(2):481-8
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted single-shot echo-planar imaging with parallel technique in assessment of endometrial cancer.
  • OBJECTIVE: The purposes of this study were to determine the feasibility of diffusion-weighted imaging (DWI) with a single-shot echo-planar sequence and parallel technique for depicting endometrial cancer and to examine the role of this technique in preoperative assessment.
  • SUBJECTS AND METHODS: A total of 31 patients were recruited for MRI evaluation of suspicious endometrial lesions found on transvaginal sonography.
  • Twenty-four of the patients were proved to have endometrial cancer (patient group), and seven to have benign diseases (control group).
  • The apparent diffusion coefficient of endometrial cancer in the patient group and of normal endometrium in the control group were measured on the apparent diffusion coefficient map of each diffusion-weighted image and compared for the two groups.
  • RESULTS: The mean apparent diffusion coefficient of endometrial cancer was 0.864 x 10(-3) mm2/s and that of benign endometrial lesions was 1.277 x 10(-3) mm2/s.
  • In five cases, DWI provided information about tumor extent and depicted the tumor focus, findings that changed preoperative staging.
  • CONCLUSION: DWI performed with parallel imaging technique has potential as a method for differentiating benign from malignant endometrial lesions.
  • It also provides valuable information for preoperative evaluation and should be considered part of routine preoperative MRI evaluation for endometrial cancer.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Echo-Planar Imaging / methods. Endometrial Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212236.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


63. Fadare O, Wang SA, Renshaw IL: Does the radiofrequency impedance-controlled endometrial ablation have any morphologic effects on uterine leiomyomata? Report of 3 cases. Diagn Pathol; 2008;3:28
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does the radiofrequency impedance-controlled endometrial ablation have any morphologic effects on uterine leiomyomata? Report of 3 cases.
  • A variety of novel endometrial ablation technologies are now in routine use.
  • The NovaSure [Hologic Corporation, Marlborough, MA, USA] endometrial ablation system is one of several available second-generation technologies and its particular endometrial ablative power is based on the delivery of radiofrequency energy.
  • The present analysis was designed to decipher any histologic changes (if any) associated with the NovaSure endometrial ablation system relative to benign smooth muscle tumors of the uterine corpus.
  • Over a one-year period, 3 uteri that had previously undergone the NovaSure endometrial ablation and which also had leiomyomatous mass lesions were evaluated.
  • Since the presence or absence of tumor necrosis is one histologic criterion by which malignant potential is assigned to uterine smooth muscle neoplasms, defining any extrinsic processes that may establish, or contribute to this finding is clinically relevant.
  • The findings reported herein suggests that if a leiomyoma that was obtained from a patient that had recently undergone the NovaSure endometrial ablation displays any degenerative changes such as necrosis, the changes are probably not attributable to the ablation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2007 Dec;21(6):989-94 [17490913.001]
  • [Cites] J Reprod Med. 2007 Jun;52(6):467-72 [17694962.001]
  • [Cites] Arch Pathol Lab Med. 2005 Sep;129(9):1175-8 [16119995.001]
  • [Cites] J Minim Invasive Gynecol. 2007 Jan-Feb;14(1):85-90 [17218236.001]
  • [Cites] J Obstet Gynaecol Can. 2005 May;27(5):473-6 [16100642.001]
  • (PMID = 18593468.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2491603
  •  go-up   go-down


64. Kalyanasundaram K, Ganesan R, Perunovic B, McCluggage WG: Diffusely infiltrating endometrial carcinomas with no stromal response: report of a series, including cases with cervical and ovarian involvement and emphasis on the potential for misdiagnosis. Int J Surg Pathol; 2010 Apr;18(2):138-43
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusely infiltrating endometrial carcinomas with no stromal response: report of a series, including cases with cervical and ovarian involvement and emphasis on the potential for misdiagnosis.
  • Endometrial carcinomas, particularly of endometrioid type, can invade the myometrium or cervix without eliciting a stromal desmoplastic or inflammatory response and have been referred to as diffusely infiltrating endometrial carcinomas.
  • This study describes a series of 14 endometrial carcinomas infiltrating as single "naked" glands without a stromal response.
  • Several of the cases were seen in consultation and the pattern of infiltration raised a number of differential diagnoses, both benign and malignant, depending on the site of tumor involvement, including adenomyosis, adenomyoma, primary endocervical glandular lesions, cervical mesonephric remnants, endometriosis or tuboendometrioid metaplasia, and ovarian cortical inclusion cysts.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnostic Errors / prevention & control. Female. Humans. Middle Aged. Myometrium / pathology. Neoplasm Invasiveness. Stromal Cells / pathology


65. Kamat AA, Coffey D, Merritt WM, Nugent E, Urbauer D, Lin YG, Edwards C, Broaddus R, Coleman RL, Sood AK: EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer; 2009 Jun 15;115(12):2684-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer.
  • The objective of the current investigation was to study the role of EphA2 in endometrial cancer and its relation to steroid hormone receptor expression.
  • METHODS: EphA2, estrogen receptor (ER), progesterone receptor (PR), and Ki-67 expression levels were evaluated using immunohistochemistry in 139 endometrioid endometrial carcinoma (EEC) samples and in 10 benign endometrial samples.
  • RESULTS: High expression of EphA2 was detected in 48% of EEC samples versus 10% of benign samples.
  • EphA2 overexpression was associated significantly with high disease stage (P = .04), high tumor grade (P = .003), increased depth of myometrial invasion (P = .05), low ER expression (P = .01), low PR expression (P = .006), and high Ki-67 expression (P = .04).
  • Low ER and PR expression levels were associated with high tumor grade, positive lymph nodes, high Ki-67 expression, and high EphA2 expression.
  • Thus, EphA2 may be an important therapeutic target, especially in patients with hormone receptor-negative endometrial carcinoma.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 American Cancer Society.
  • [Cites] J Cell Biochem. 2002;85(4):714-20 [11968011.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2840-7 [12019162.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1037-42 [12651595.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3425-9 [12810680.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5145-50 [15297418.001]
  • [Cites] Gynecol Oncol. 1990 Jul;38(1):59-65 [2141316.001]
  • [Cites] Mol Cell Biol. 1990 Dec;10(12):6316-24 [2174105.001]
  • [Cites] Oncogene. 1994 May;9(5):1461-7 [8152808.001]
  • [Cites] Gynecol Oncol. 1995 Mar;56(3):406-11 [7705676.001]
  • [Cites] Science. 1995 Apr 28;268(5210):567-9 [7536959.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1268-74 [7590703.001]
  • [Cites] N Engl J Med. 1996 Aug 29;335(9):640-9 [8692240.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jun;6(6):462-75 [15928710.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1707-14 [16551853.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1558-70 [17077358.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):332-40 [17154180.001]
  • [Cites] Cancer Biol Ther. 2006 Dec;5(12):1708-13 [17106249.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Prostate. 1999 Dec 1;41(4):275-80 [10544301.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1736-44 [10561210.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5614-9 [11114742.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2301-6 [11280802.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3250-5 [11309274.001]
  • [Cites] Surg Oncol Clin N Am. 2001 Apr;10(2):271-88, viii [11382587.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):613-8 [12576426.001]
  • (PMID = 19396818.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA101642; United States / NCI NIH HHS / CA / CA101642-05; United States / NCI NIH HHS / CA / T32 CA101642-05; United States / NCI NIH HHS / CA / P50 CA098258; United States / NCI NIH HHS / CA / P50 CA083639-10; United States / NCI NIH HHS / CA / P50 CA083639
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, EphA2
  • [Other-IDs] NLM/ NIHMS241018; NLM/ PMC3139331
  •  go-up   go-down


66. Granovsky-Grisaru S, Zaidoun S, Grisaru D, Yekel Y, Prus D, Beller U, Bar-Shavit R: The pattern of Protease Activated Receptor 1 (PAR1) expression in endometrial carcinoma. Gynecol Oncol; 2006 Dec;103(3):802-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pattern of Protease Activated Receptor 1 (PAR1) expression in endometrial carcinoma.
  • While the role of either soluble or matrix-immobilized protease in tumor invasion is well established, the part of cell surface PARs is beginning to emerge.
  • We sought to investigate the expression pattern of Protease Activated Receptor 1 (hPar1) in endometrial carcinoma, the most common type of gynecological malignancy.
  • METHODS: Tissue biopsy specimens taken from seventy-four formalin-fixed, paraffin-embedded endometrial tissue blocks were obtained from archival material.
  • RESULTS: The levels of hPar1 mRNA and protein were high and abundant in high-grade endometrial carcinoma, regardless of the histological subtype.
  • In contrast, no hPar1 was detected in endometrial epithelia with conserved glandular structure represented by normal, hyperplastic or low-grade carcinomas.
  • CONCLUSIONS: PAR1 over-expression is selectively confined to the highly aggressive, high-grade endometrial carcinoma and absent in tissue obtained from benign endometrium or low-grade endometrial cancer.
  • This finding highlights the significance of hPar1 gene involvement in invasive endometrial carcinoma and appoints it an attractive candidate for anti-cancer therapy.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Receptor, PAR-1 / metabolism
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Neoplasm Staging. RNA, Messenger / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875721.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptor, PAR-1
  •  go-up   go-down


67. Blumenthal GM, Dennis PA: PTEN hamartoma tumor syndromes. Eur J Hum Genet; 2008 Nov;16(11):1289-300
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PTEN hamartoma tumor syndromes.
  • The PTEN hamartoma tumor syndromes (PHTS) are a collection of rare clinical syndromes characterized by germline mutations of the tumor suppressor PTEN.
  • These syndromes are driven by cellular overgrowth, leading to benign hamartomas in virtually any organ.
  • Cowden syndrome (CS), the prototypic PHTS syndrome, is associated with increased susceptibility to breast, thyroid, and endometrial cancer.


68. Trahan S, Têtu B, Raymond PE: Serous papillary carcinoma of the endometrium arising from endometrial polyps: a clinical, histological, and immunohistochemical study of 13 cases. Hum Pathol; 2005 Dec;36(12):1316-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous papillary carcinoma of the endometrium arising from endometrial polyps: a clinical, histological, and immunohistochemical study of 13 cases.
  • Serous papillary carcinoma is an aggressive tumor.
  • Point mutations in the p53 suppressor gene might explain in part the rapid growth of this malignant tumor and its unfavorable outcome.
  • The aims of this study were to evaluate the behavior of serous papillary carcinoma developing in endometrial polyps and to assess the p53 protein overexpression.
  • Thirteen serous papillary carcinomas arising from benign polyps of the endometrium were identified.
  • A serous papillary carcinoma arising from benign polyps of the endometrium remains a malignant neoplasia with an unfavorable outcome even if the primary tumor is limited to the polyp.
  • The high rate of protein p53 overexpression suggests that a p53 gene mutation occurs early in the disease and might explain the rapid growth of the tumor.
  • [MeSH-major] Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / pathology. Polyps / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Disease-Free Survival. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Tumor Suppressor Protein p53 / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16311126.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


69. Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Buza N, Tavassoli FA, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD: Serum amyloid A: a novel biomarker for endometrial cancer. Cancer; 2010 Feb 15;116(4):843-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum amyloid A: a novel biomarker for endometrial cancer.
  • BACKGROUND: The authors investigated the expression of serum amyloid A (SAA) in endometrial endometrioid carcinoma and evaluated its potential as a serum biomarker.
  • METHODS: SAA gene and protein expression levels were evaluated in endometrial endometrioid carcinoma and normal endometrial tissues, by real-time polymerase chain reaction (PCR), immunohistochemistry (IHC), and flow cytometry.
  • SAA concentration in 194 serum samples from 50 healthy women, 42 women with benign diseases, and 102 patients including 49 grade 1, 38 grade 2, and 15 grade 3 endometrial endometrioid carcinoma was also studied by a sensitive bead-based immunoassay.
  • RESULTS: SAA gene expression levels were significantly higher in endometrial endometrioid carcinoma when compared with normal endometrial tissues (mean copy number by real-time PCR = 182 vs 1.9; P = .001).
  • IHC revealed diffuse cytoplasmic SAA protein staining in poorly differentiated endometrial endometrioid carcinoma tissues.
  • High intracellular levels of SAA were identified in primary endometrial endometrioid carcinoma cell lines evaluated by flow cytometry, and SAA was found to be actively secreted in vitro.
  • SAA concentrations (microg/mL) had medians of 6.0 in normal healthy women and 6.0 in patients with benign disease (P = .92).
  • In contrast, SAA values in the serum of endometrial endometrioid carcinoma patients had a median of 23.7, significantly higher than those of the healthy group (P = .001) and benign group (P = .001).
  • Patients harboring G3 endometrial endometrioid carcinoma were found to have SAA concentrations significantly higher than those of G1/G2 patients.
  • CONCLUSIONS: SAA is not only a liver-secreted protein, but is also an endometrial endometrioid carcinoma cell product.
  • SAA is expressed and actively secreted by G3 endometrial endometrioid carcinoma, and it is present in high concentration in the serum of endometrial endometrioid carcinoma patients.
  • SAA may represent a novel biomarker for endometrial endometrioid carcinoma to monitor disease recurrence and response to therapy.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Hematol. 2000 Jan;7(1):64-9 [10608507.001]
  • [Cites] Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1090-6 [18021217.001]
  • [Cites] Proteomics. 2003 Sep;3(9):1720-4 [12973732.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):43-52 [14734450.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5293; author reply 5293-4 [15297433.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Am J Obstet Gynecol. 1986 Nov;155(5):1097-102 [3465243.001]
  • [Cites] Am J Obstet Gynecol. 1990 Oct;163(4 Pt 1):1204-9 [2220931.001]
  • [Cites] N Engl J Med. 1996 Aug 29;335(9):640-9 [8692240.001]
  • [Cites] Obstet Gynecol. 1997 Sep;90(3):441-7 [9277659.001]
  • [Cites] J Histochem Cytochem. 1998 Dec;46(12):1377-84 [9815279.001]
  • [Cites] Clin Chem Lab Med. 1999 Apr;37(4):381-8 [10369107.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1561-73 [15785748.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7677-82 [15890779.001]
  • [Cites] J Reprod Med. 2005 Aug;50(8):585-90 [16220763.001]
  • [Cites] J Histochem Cytochem. 2006 Jan;54(1):63-73 [16116035.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):84-93 [17063306.001]
  • [Cites] Acta Obstet Gynecol Scand. 2006;85(12):1501-5 [17260229.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Br J Cancer. 2008 Sep 2;99(5):768-73 [18682706.001]
  • [Cites] Am J Obstet Gynecol. 2000 Jun;182(6):1328-34 [10871446.001]
  • (PMID = 20041483.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA122728-01A2; United States / NCI NIH HHS / CA / R01 CA122728-01A2; United States / NCI NIH HHS / CA / R01 CA122728; United States / NCI NIH HHS / CA / CA-16,359; United States / NCI NIH HHS / CA / P30 CA016359
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Serum Amyloid A Protein
  • [Other-IDs] NLM/ NIHMS158487; NLM/ PMC2819580
  •  go-up   go-down


70. Bar JK, Słomska I, Rabczyńki J, Noga L, Gryboś M: Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors. Int J Gynecol Cancer; 2009 Nov;19(8):1322-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors.
  • METHODS: p53 protein expression was evaluated on tissues from malignant and benign ovarian tumors.
  • In the total group of ovarian carcinomas, significant differences were observed in p53 protein overexpression between well (G1) and poor (G3) tumor grades (P = 0.005) and between serous and endometrioid types of tumor (P = 0.04), whereas p53-Ser20 phosphorylation was associated with advanced International Federation of Gynecology and Obstetrics stage (P = 0.004) and high tumor grade (P = 0.02).
  • In p53-positive ovarian carcinomas, p53-Ser392 phosphorylation was associated with advanced tumor stage (P = 0.02) and high tumor grade (P = 0.049).
  • p53-Ser20 phosphorylation was associated with low tumor grade of p53-positive ovarian carcinomas (P = 0.02) and with high tumor grade of p53-negative ovarian carcinomas (P = 0.02).
  • CONCLUSIONS: These results revealed that p53 phosphorylation at Ser20 and Ser392 is an early event in ovarian tumor development.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Serous / metabolism. Endometrial Neoplasms / metabolism. Neoplasms / metabolism. Ovarian Neoplasms / metabolism. Serine / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Phosphorylation. Prognosis. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • Hazardous Substances Data Bank. L-SERINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009884.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 452VLY9402 / Serine
  •  go-up   go-down


71. Jarboe EA, Pizer ES, Miron A, Monte N, Mutter GL, Crum CP: Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma. Mod Pathol; 2009 Mar;22(3):345-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma.
  • Both serous intraepithelial carcinoma and endometrial glandular dysplasia are associated with uterine serous carcinoma.
  • We analyzed normal and neoplastic endometrium for a similar entity.
  • In total 10 endometrial polyps involved by intraepithelial and/or invasive carcinoma and 137 benign polyps were studied.
  • Of 137 benign polyps (4%), 6 contained p53 signatures.
  • DNA damage (gamma-H2AX) was demonstrated in both p53 signatures and adjacent carcinomas but not in benign polyps.
  • The significance of p53 signatures in benign conditions (polyps) remains to be determined.
  • The role of the p53 signature in early serous neoplasia is discussed.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3985-90 [17761984.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):161-9 [17255760.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2263-9 [18369088.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):168-73 [18342932.001]
  • [Cites] Mod Pathol. 2008 Aug;21(8):937-42 [18500258.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4160-5 [18757330.001]
  • [Cites] Gynecol Oncol. 2008 Nov;111(2):226-32 [18718648.001]
  • [Cites] Am J Pathol. 1999 Nov;155(5):1467-71 [10550302.001]
  • [Cites] Int J Surg Pathol. 2004 Oct;12(4):319-31 [15494858.001]
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):93-108 [7102898.001]
  • [Cites] Obstet Gynecol. 1987 Jan;69(1):109-13 [3796910.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1260-7 [7590702.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1268-74 [7590703.001]
  • [Cites] Mol Cell. 2005 Jun 10;18(6):617-22 [15949437.001]
  • [Cites] Obstet Gynecol. 2005 Dec;106(6):1327-34 [16319259.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):230-6 [16434898.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • [Cites] Gynecol Oncol. 2007 Jan;104(1):7-10 [16962648.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jan;27(1):1-9 [18156967.001]
  • (PMID = 19151662.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA105009-05; United States / NCI NIH HHS / CA / P50 CA105009; United States / NCI NIH HHS / CA / R21 CA124688-02; United States / NCI NIH HHS / CA / R21 CA124688; United States / NCI NIH HHS / CA / K08 CA108748; United States / NCI NIH HHS / CA / CA124688-02; United States / NCI NIH HHS / CA / 1R21CA124688-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / H2AFX protein, human; 0 / Histones; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS77435; NLM/ PMC2649686
  •  go-up   go-down


72. Rabban JT, McAlhany S, Lerwill MF, Grenert JP, Zaloudek CJ: PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma. Am J Surg Pathol; 2010 Feb;34(2):137-46
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma.
  • The differential diagnosis of exuberant mesonephric hyperplasia includes minimal deviation adenocarcinoma of the cervix, a tumor with deceptively bland morphology for which no reliable diagnostic biomarkers currently exist.
  • PAX2 encodes a transcription factor necessary in the development of the Wolffian duct system, and the protein is expressed in several tumors of mesonephric origin, including renal cell carcinoma, Wilm tumor, and nephrogenic adenoma.
  • Most (11 of 15) stage II endometrial endometrioid adenocarcinomas lacked PAX2 expression but 1 of 10 grade 1 tumors and 3 of 5 grade 2 tumors did express PAX2.
  • Overall, a strong, diffuse nuclear PAX2 expression pattern in a cervical glandular proliferation predicts a benign diagnosis (positive predictive value 90%, negative predictive value 98%; P<0.001); however, PAX2 should not be interpreted in isolation from the architectural and cytologic features of the lesion as it may be expressed in some stage II endometrial adenocarcinomas involving the cervix.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Cervix Uteri / pathology. Mesonephros / pathology. Mullerian Ducts / pathology. PAX2 Transcription Factor / metabolism. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor. Cell Nucleus / metabolism. Cell Nucleus / pathology. Diagnosis, Differential. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / metabolism. Immunohistochemistry / methods. Neoplasm Staging. Precancerous Conditions / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20061933.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human
  •  go-up   go-down


73. DeSouza LV, Grigull J, Ghanny S, Dubé V, Romaschin AD, Colgan TJ, Siu KW: Endometrial carcinoma biomarker discovery and verification using differentially tagged clinical samples with multidimensional liquid chromatography and tandem mass spectrometry. Mol Cell Proteomics; 2007 Jul;6(7):1170-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial carcinoma biomarker discovery and verification using differentially tagged clinical samples with multidimensional liquid chromatography and tandem mass spectrometry.
  • M. (2005) Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cleavable ICAT with multidimensional liquid chromatography and tandem mass spectrometry. J. Proteome Res.
  • 4, 377-386) to discriminate malignant and benign endometrial tissue samples was verified in a 40-sample iTRAQ (isobaric tags for relative and absolute quantitation) labeling study involving normal proliferative and secretory samples and Types I and II endometrial cancer samples.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Endometrial Neoplasms / metabolism. Proteome / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374602.001).
  • [ISSN] 1535-9476
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteome
  •  go-up   go-down


74. Tsao KC, Hong JH, Wu TL, Chang PY, Sun CF, Wu JT: Elevation of CA 19-9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis. J Clin Lab Anal; 2007;21(3):193-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevation of CA 19-9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis.
  • As the best-known tumor marker for ovarian carcinoma, CA 125 has also been commonly used to monitor patients with common benign gynecologic diseases such as endometriosis and leiomyoma.
  • Both of these benign tumors are known to be at risk of developing into cancer.
  • During the screening of an asymptomatic population with multiple tumor markers, including alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), CA 125, CA 19-9, CA 15-3, chromogranin A (CgA), and squamous cell carcinoma antigen (SCC), we have detected elevated tumor markers in 142 individuals; 19 of them were diagnosed with endometriosis or leiomyoma or both.
  • In addition to the detection of elevation of CA 125 in these benign tumors, elevated CA 19-9 or CgA was also found in these patients with endometriosis or leiomyoma.
  • It appears that instead of monitoring only CA 125, as is traditionally done, multiple tumor markers, including CA 19-9, CgA, and CA 125, should be measured simultaneously in women with clinical disorders associated with the ovary or uterus in order to detect gynecologic benign tumors and in order to prevent further development of cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. CA-19-9 Antigen / blood. Chromogranin A / blood. Endometrial Neoplasms / blood. Endometriosis / blood. Leiomyoma / blood


75. Abu J, Ireland D, Brown L: Adenosarcoma of an endometrial polyp in a 27-year-old nulligravida: a case report. J Reprod Med; 2007 Apr;52(4):326-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosarcoma of an endometrial polyp in a 27-year-old nulligravida: a case report.
  • BACKGROUND: Endometrial adenosarcoma is a rare tumor first described by Clement and Scully in 1974.
  • It consists of benign or atypical neoplastic glands within a sarcomatous stroma and represents approximately 8% of all uterine sarcomas.
  • CASE: Endometrial polyp adenosarcoma occurred in a 27-year-old, nulligravid woman who presented with intermenstrual and postcoital bleeding.
  • CONCLUSION: A clinical dilemma was encountered in the management of a young woman with endometrial polyp adenosarcoma because of the necessity to preserve her fertility.
  • [MeSH-major] Adenosarcoma / surgery. Endometrial Neoplasms / surgery. Fertility / physiology. Polyps / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17506376.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Ratner ES, Tuck D, Richter C, Nallur S, Patel RM, Schultz V, Hui P, Schwartz PE, Rutherford TJ, Weidhaas JB: MicroRNA signatures differentiate uterine cancer tumor subtypes. Gynecol Oncol; 2010 Sep;118(3):251-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA signatures differentiate uterine cancer tumor subtypes.
  • OBJECTIVE: Endometrial cancer (EC) is the most common gynecologic malignancy.
  • METHODS: Ninety-five fresh/frozen and paraffin-embedded samples of endometrial type I and II cancer, carcinosarcomas and benign endometrial samples were collected.
  • RESULTS: Distinct miRNA signatures in tumor versus normal samples and in endometrioid vs. uterine papillary serous carcinomas exist.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] Gynecol Oncol. 2000 Apr;77(1):1-7 [10739683.001]
  • [Cites] Nat Cell Biol. 2010 Apr;12(4):372-9 [20190740.001]
  • [Cites] Int J Gynecol Cancer. 2002 Nov-Dec;12(6):687-90 [12445244.001]
  • [Cites] Hokkaido Igaku Zasshi. 2003 Mar;78(2):117-27 [12704854.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2003 Aug;32(4):314-8 [14514374.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5675-82 [14654551.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Am J Clin Pathol. 1982 May;77(5):534-40 [7081149.001]
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):93-108 [7102898.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Cancer. 1983 May 1;51(9):1705-9 [6831367.001]
  • [Cites] Am J Obstet Gynecol. 1991 Jan;164(1 Pt 1):15-21 [1670908.001]
  • [Cites] Cancer. 1991 Jun 15;67(12):3093-103 [2044053.001]
  • [Cites] Gynecol Oncol. 1992 Dec;47(3):298-305 [1473741.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4667-70 [8062261.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):264-8 [8088602.001]
  • [Cites] Obstet Gynecol. 1995 May;85(5 Pt 1):729-34 [7724103.001]
  • [Cites] N Engl J Med. 1996 Aug 29;335(9):640-9 [8692240.001]
  • [Cites] J Soc Gynecol Investig. 1996 May-Jun;3(3):99-105 [8796816.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3935-40 [9307275.001]
  • [Cites] Int J Cancer. 1997 Sep 4;72(5):821-7 [9311600.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):70-5 [9345359.001]
  • [Cites] Gynecol Oncol. 1998 Jun;69(3):253-7 [9648597.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Future Oncol. 2006 Feb;2(1):73-82 [16556074.001]
  • [Cites] Am J Pathol. 2006 Nov;169(5):1812-20 [17071602.001]
  • [Cites] Rom J Morphol Embryol. 2006;47(2):137-41 [17106521.001]
  • [Cites] PLoS One. 2006;1:e116 [17205120.001]
  • [Cites] DNA Cell Biol. 2007 May;26(5):283-92 [17504024.001]
  • [Cites] DNA Cell Biol. 2007 May;26(5):293-300 [17504025.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5699-707 [17575136.001]
  • [Cites] Urol Oncol. 2007 Sep-Oct;25(5):387-92 [17826655.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8699-707 [17875710.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Feb;135(2):255-60; discussion 260 [18242245.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Oncogene. 2008 Mar 13;27(12):1788-93 [17891175.001]
  • [Cites] Genes Dev. 2008 Apr 1;22(7):894-907 [18381893.001]
  • [Cites] Vopr Onkol. 2007;53(6):682-9 [18416138.001]
  • [Cites] Nat Cell Biol. 2008 May;10(5):593-601 [18376396.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 13;105(19):7004-9 [18458333.001]
  • [Cites] FEBS Lett. 2008 Oct 29;582(25-26):3663-8 [18840437.001]
  • [Cites] Cancer Res. 2009 Feb 1;69(3):1135-42 [19155302.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1814-9 [19188590.001]
  • [Cites] Int J Cancer. 2009 May 1;124(9):2236-42 [19127597.001]
  • [Cites] Cancer Res. 2009 Mar 15;69(6):2287-95 [19244118.001]
  • [Cites] PLoS One. 2009;4(10):e7629 [19893619.001]
  • [Cites] Genes Dev. 2009 Dec 15;23(24):2839-49 [20008935.001]
  • [Cites] Cancer Res. 2010 Mar 1;70(5):1916-24 [20160038.001]
  • [Cites] J Biomed Biotechnol. 2010;2010:369549 [20300586.001]
  • [Cites] J Clin Pathol. 2002 May;55(5):321-5 [11986333.001]
  • (PMID = 20542546.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA124484-01A1; United States / NCI NIH HHS / CA / K08 CA124484; United States / NIDDK NIH HHS / DK / P30 DK072442; United States / NCI NIH HHS / CA / K08 CA124484-01A1; United States / NCI NIH HHS / CA / U10 CA021661; United States / NCI NIH HHS / CA / U10CA21661
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  • [Other-IDs] NLM/ NIHMS208098; NLM/ PMC2918705
  •  go-up   go-down


77. Shah SS, Mazur MT: Endometrial eosinophilic syncytial change related to breakdown: immunohistochemical evidence suggests a regressive process. Int J Gynecol Pathol; 2008 Oct;27(4):534-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial eosinophilic syncytial change related to breakdown: immunohistochemical evidence suggests a regressive process.
  • Eosinophilic syncytial change (ESC), also known as papillary syncytial change, occurs in association with endometrial breakdown and bleeding, especially in nonphysiological conditions.
  • When prominent, this morphological alteration yields a pattern of eosinophilic epithelial cells, often in pseudopapillary arrangements that can mimic cellular changes seen in metaplastic and atypical endometrium.
  • Our methodology involved a retrospective immunohistochemical study on endometrial biopsies with proliferation markers Ki-67 (MIB-1 antibody) and phosphohistone H3 Ser 28 (pHH3) in 15 cases of multifocal ESC associated with benign endometrium, 5 cases of atypical hyperplasia, and 7 cases of endometrial carcinoma.
  • On immunohistochemical analysis, the Ki-67 labeling index was 1.3% for cases of ESC (mean age, 53 yr), 15.8% in atypical hyperplasia (mean age, 51.6 yr), and 42.6% in endometrial carcinoma (mean age, 68.1 yr).
  • In the endometrial cancers, the Ki-67 proliferative index was 10.6% for FIGO grade 1 tumors (n=3), 27.6% for grade 2 tumor (n=1), and 79.6% for serous carcinoma (n=3).
  • The mitotic index calculated from pHH3 immunostaining was zero in all cases of ESC, whereas it was 2.3% in atypical hyperplasia and 4.8% in endometrial carcinomas (2.4% for grade 1, 3% for grade 2, and 7.8% for serous).
  • Furthermore, when there is a question of whether eosinophilic endometrial epithelium represents this change, a combination of Ki-67 and pHH3 immunostains can be helpful in distinguishing this entity from more significant processes including carcinoma.
  • [MeSH-major] Endometrium / pathology. Eosinophils / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Cell Growth Processes / physiology. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / pathology. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753967.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


78. Dubé V, Grigull J, DeSouza LV, Ghanny S, Colgan TJ, Romaschin AD, Siu KW: Verification of endometrial tissue biomarkers previously discovered using mass spectrometry-based proteomics by means of immunohistochemistry in a tissue microarray format. J Proteome Res; 2007 Jul;6(7):2648-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Verification of endometrial tissue biomarkers previously discovered using mass spectrometry-based proteomics by means of immunohistochemistry in a tissue microarray format.
  • Here, we report results of a verification exercise involving six candidate endometrial cancer biomarkers previously discovered using mass-tagging and multidimensional liquid chromatography/tandem mass spectrometry (DeSouza L., et al. J.
  • A panel of the three best-performing biomarkers, chaperonin 10, pyruvate kinase M2, and alpha-1-antitrypsin, achieved a sensitivity of 0.85, specificity of 0.93, predictive value of 0.90, and positive predictive value of 0.88 in discriminating malignant from benign endometrium.
  • [MeSH-major] Biomarkers, Tumor / analysis. Biomarkers, Tumor / standards. Endometrial Neoplasms / chemistry. Immunohistochemistry / methods. Tissue Array Analysis / methods
  • [MeSH-minor] Chromatography, Liquid. Endometrium / chemistry. Endometrium / pathology. Female. Humans. Mass Spectrometry. Proteomics / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17552551.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


79. Bradley WH, Lima PH, Rodgers L, Blomquist CH, Downs LS: Endometrial carcinoma expresses an increased cathepsin B/D ratio. Gynecol Oncol; 2008 Jan;108(1):84-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial carcinoma expresses an increased cathepsin B/D ratio.
  • OBJECTIVES: Cathepsins B and D belong to a family of proteases involved in tumor invasion and metastasis.
  • As such they may function as biomarkers for the aggressiveness of a given tumor.
  • 4 groups were established: benign tissue, stage I/grade 1, stage i/grade 3, and stage IIIC/any grade.
  • RESULTS: A significantly increased level of cathepsin B activity was seen in malignant tissue specimens when compared to benign tissue.
  • The cathepsin B/D ratio confirmed and was required to detect the significance of this distinction for each malignant group when compared to benign samples.
  • CONCLUSIONS: Malignant endometrium displays increased cathepsin B activity when compared benign samples.
  • The cathepsin B/D ratio is increased for each of the malignant groups studied when compared directly to benign endometrium.
  • This ratio may serve to distinguish malignant from benign tumor samples and may be a constitutive change in the malignant transformation.
  • [MeSH-major] Cathepsin B / biosynthesis. Cathepsin D / biosynthesis. Endometrial Neoplasms / enzymology
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17980407.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.22.1 / Cathepsin B; EC 3.4.23.5 / Cathepsin D
  •  go-up   go-down


80. Strissel PL, Ellmann S, Loprich E, Thiel F, Fasching PA, Stiegler E, Hartmann A, Beckmann MW, Strick R: Early aberrant insulin-like growth factor signaling in the progression to endometrial carcinoma is augmented by tamoxifen. Int J Cancer; 2008 Dec 15;123(12):2871-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early aberrant insulin-like growth factor signaling in the progression to endometrial carcinoma is augmented by tamoxifen.
  • In addition to the beneficial effect, tamoxifen is one risk factor for endometrial carcinoma (EnCa) development.
  • We hypothesized that, (1) dysregulation of gene expression and protein phosphorylation of the insulin-like growth factor (IGF) and steroid hormone receptor-signaling occur early in benign endometrial tissues and (2) signaling differences would be detected between patients with or without tamoxifen treatment.
  • Seventy-eight tissues, including 2 benign cohorts from patients treated with (n = 24) or without tamoxifen (n = 28) (hyperproliferative endometrium, hyperplasia, polyps), EnCa (n = 12) with endometrium controls (n = 14) were analyzed for expression of 15 genes from the IGF and steroid hormone receptor-signaling, including the target genes Syncytin-1, PAX2 and c-myc.
  • Compared to controls similar significant deregulation of IGF and steroid hormone receptor-signaling, Syncytin-1 and PAX2 occurred in both benign cohorts, irrelevant of tamoxifen treatment.
  • Comparing both benign cohorts with and without tamoxifen significant expression differences were noted.
  • Increased total protein and phosphorylation of pERalpha-Ser118, pPTEN-Thr380, pAKT-Thr308, pAKT-Ser473, pmTOR-Ser2448 and Syncytin-1 were noted in early benign tissue stages associating with tamoxifen, especially polyps.
  • This study supports that dysregulated IGF and steroid hormone receptor signaling is prominent in endometrial benign stages and these alterations could represent clinical indicators for the risk of EnCa and also help in development of new therapies.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Biomarkers, Tumor / metabolism. Carcinoma / etiology. Endometrial Neoplasms / etiology. Estrogen Receptor Modulators / adverse effects. Insulin-Like Growth Factor I / metabolism. Tamoxifen / adverse effects

  • Hazardous Substances Data Bank. TAMOXIFEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18814240.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Estrogen Receptor Modulators; 0 / Gonadal Steroid Hormones; 094ZI81Y45 / Tamoxifen; 67763-96-6 / Insulin-Like Growth Factor I; EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


81. Mhawech-Fauceglia P, Saxena R, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, Penetrante R: Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis. J Clin Pathol; 2007 Jun;60(6):709-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis.
  • AIMS AND METHODS: To determine Pax-5 expression in other tumour types, immunohistochemistry was performed on 3758 benign and malignant tumours using multiple tumour microarrays, as well as on whole sections.
  • In addition, Pax-5 was seen in 24/34 (70.6%) Merkel cell carcinomas, 42/53 (79.2%) small cell carcinomas, 1/164 (0.6%) breast carcinomas, 2/204 (1%) endometrial adenocarcinomas and 1/452 (0.2%) urothelial carcinoma of the bladder.
  • [MeSH-major] B-Cell-Specific Activator Protein / metabolism. Biomarkers, Tumor / metabolism. Neoplasms / metabolism
  • [MeSH-minor] Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / metabolism. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Diagnosis, Differential. Hodgkin Disease / diagnosis. Hodgkin Disease / metabolism. Humans. Immunoenzyme Techniques. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / metabolism. Neoplasm Proteins / metabolism. Protein Array Analysis / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 2001 Jun;14(6):779-90 [11420047.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):687-92 [15832095.001]
  • [Cites] Trends Genet. 2002 Jan;18(1):41-7 [11750700.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1343-50 [12360049.001]
  • [Cites] Int Urol Nephrol. 2002-2003;34(4):495-501 [14577491.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):994-1000 [14608532.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):122-8 [14745734.001]
  • [Cites] Carcinogenesis. 2004 Oct;25(10):1839-46 [15155532.001]
  • [Cites] Am J Clin Pathol. 2004 Nov;122(5):721-7 [15491968.001]
  • [Cites] Mech Dev. 1992 Nov;39(1-2):29-39 [1283313.001]
  • [Cites] Genomics. 1993 Dec;18(3):705-8 [7508415.001]
  • [Cites] C R Acad Sci III. 1995 Jan;318(1):57-66 [7757805.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5709-13 [7777574.001]
  • [Cites] Genes Dev. 1997 Feb 15;11(4):476-91 [9042861.001]
  • [Cites] J Immunol. 1997 Apr 1;158(7):3197-204 [9120274.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 27;94(11):5703-8 [9159136.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Clin Cancer Res. 1995 Feb;1(2):207-14 [9815975.001]
  • [Cites] Gen Physiol Biophys. 1998 Sep;17(3):211-24 [9834843.001]
  • [Cites] BJU Int. 1999 Jun;83(9):1039-44 [10368252.001]
  • [Cites] Nature. 1999 Oct 7;401(6753):556-62 [10524622.001]
  • [Cites] Int J Cancer. 2001 Aug 15;93(4):459-67 [11477548.001]
  • (PMID = 16837628.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / PAX5 protein, human
  • [Other-IDs] NLM/ PMC1955074
  •  go-up   go-down


82. Guo J, Yang EC, Desouza L, Diehl G, Rodrigues MJ, Romaschin AD, Colgan TJ, Siu KW: A strategy for high-resolution protein identification in surface-enhanced laser desorption/ionization mass spectrometry: calgranulin A and chaperonin 10 as protein markers for endometrial carcinoma. Proteomics; 2005 May;5(7):1953-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A strategy for high-resolution protein identification in surface-enhanced laser desorption/ionization mass spectrometry: calgranulin A and chaperonin 10 as protein markers for endometrial carcinoma.
  • Here we demonstrate in an examination of both malignant and nonmalignant endometrial tissue homogenates that high mass accuracy and resolution in the MS stage are crucial.
  • Analyses on a cohort of 44 endometrial homogenates showed 22 out of 23 nonmalignant samples had nondetectable to very low abundance of chaperonin 10 and calgranulin A; 17 of the 21 malignant samples had detectable to abundant levels of both proteins.
  • Immunohistochemical staining of a tissue microarray of 32 samples showed that approximately half of malignant endometrial tissues exhibited positive staining for calgranulin A in the malignant epithelium, while 9 out of 10 benign tissues exhibited negative epithelial staining.
  • Calgranulin A, in combination with chaperonin 10 and other proteins, may eventually constitute a panel of markers to permit diagnosis and screening of endometrial cancer.
  • [MeSH-major] Biomarkers, Tumor. Calgranulin A / metabolism. Chaperonin 10 / metabolism. Endometrial Neoplasms / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816004.001).
  • [ISSN] 1615-9853
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calgranulin A; 0 / Chaperonin 10
  •  go-up   go-down


83. Deng L, Broaddus RR, McCampbell A, Shipley GL, Loose DS, Stancel GM, Pickar JH, Davies PJ: Identification of a novel estrogen-regulated gene, EIG121, induced by hormone replacement therapy and differentially expressed in type I and type II endometrial cancer. Clin Cancer Res; 2005 Dec 1;11(23):8258-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a novel estrogen-regulated gene, EIG121, induced by hormone replacement therapy and differentially expressed in type I and type II endometrial cancer.
  • Here, we describe the expression pattern of a novel estrogen-induced gene, EIG121, in distinct types of endometrial cancer.
  • EXPERIMENTAL DESIGN: EIG121 was identified by cDNA microarray analysis of endometrial RNA from women receiving either placebo or estrogen replacement therapy.
  • The expression level of EIG121 was then measured by real-time quantitative reverse transcription-PCR in benign, hyperplastic, and malignant endometrial samples.
  • RESULTS: In postmenopausal endometrium, estrogen replacement therapy with Premarin and synthetic estrogen sulfate conjugates induced the expression of EIG121 2- and 3-fold, respectively.
  • In premenopausal endometrium, the expression of EIG121 was higher in the estrogen-dominated proliferative phase than the secretory phase.
  • In endometrial complex, hyperplasia, and endometrioid adenocarcinoma, neoplastic proliferations associated with estrogen excess, the expression of EIG121 was significantly elevated (on average 3.8-fold in hyperplasias and 21-fold in grade 1 tumors).
  • Although the level of EIG121 mRNA in grade 3 endometrioid carcinoma was still 3.5-fold of that in benign endometrium, EIG121 expression tended to decline with increasing tumor grade and disease stage.
  • Immunohistochemistry showed faint staining of normal endometrial epithelium, but intense staining of endometrioid tumors.
  • In sharp contrast, EIG121 expression was significantly suppressed in both uterine papillary serous carcinoma and uterine malignant mixed mullerian tumor, two tumors not associated with estrogen exposure, to <5% of the level in benign endometrium.
  • CONCLUSIONS: Our results suggest that EIG121 is a good endometrial biomarker associated with a hyperestrogenic state and estrogen-related type I endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Endometrial Neoplasms / genetics. Estrogen Replacement Therapy. Estrogens / therapeutic use. Gene Expression Regulation, Neoplastic / drug effects. Neoplasm Proteins / genetics
  • [MeSH-minor] Case-Control Studies. Endometrial Hyperplasia / genetics. Endometrial Hyperplasia / pathology. Estrogens, Conjugated (USP) / therapeutic use. Estrone / analogs & derivatives. Estrone / therapeutic use. Expressed Sequence Tags. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Oligonucleotide Array Sequence Analysis. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRONE .
  • SciCrunch. HGNC: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16322283.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50CA098258-01; United States / NICHD NIH HHS / HD / 5T32 HD007324-18
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Estrogens; 0 / Estrogens, Conjugated (USP); 0 / KIAA1324 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 2DI9HA706A / Estrone; QTL48N278K / estrone sulfate
  •  go-up   go-down


84. Barua A, Bradaric MJ, Kebede T, Espionosa S, Edassery SL, Bitterman P, Rotmensch J, Luborsky JL: Anti-tumor and anti-ovarian autoantibodies in women with ovarian cancer. Am J Reprod Immunol; 2007 Apr;57(4):243-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-tumor and anti-ovarian autoantibodies in women with ovarian cancer.
  • PROBLEM: There is a lack of validated marker(s) for the diagnosis of early-stage ovarian cancer (OVCA).
  • The secondary objective was to compare the prevalence of antibodies to proteins from normal ovary and ovarian tumors to determine if antibodies primarily recognize tumor antigens, as many antigens are common to tumor and normal ovary.
  • METHOD OF STUDY: Serum samples from patients with OVCA, borderline or benign ovarian tumors, endometrial cancer and healthy women were examined for anti-ovarian and anti-tumor antibodies by immunoassay.
  • RESULTS: Ovarian (81%, P < or = 0.001) and anti-tumor (69%, P < or = 0.001) autoantibodies in OVCA were significantly different from those of control sera.
  • While there were similar reactions in two-dimensional Western blots, there are differences between reactions to normal and tumor antigens and between reactions to autologous and allogeneic tumors.
  • Anti-tumor antibodies may provide a useful marker for the detection of ovarian cancer.
  • [MeSH-major] Antibodies, Neoplasm / blood. Antigens, Neoplasm / immunology. Autoantibodies / blood. Biomarkers, Tumor / blood. Ovarian Neoplasms / immunology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17362385.001).
  • [ISSN] 1046-7408
  • [Journal-full-title] American journal of reproductive immunology (New York, N.Y. : 1989)
  • [ISO-abbreviation] Am. J. Reprod. Immunol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / R01AI055060
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / Biomarkers, Tumor
  •  go-up   go-down


85. Chang YW, Hong SS, Jeen YM, Kim MK, Suh ES: Bilateral sclerosing stromal tumor of the ovary in a premenarchal girl. Pediatr Radiol; 2009 Jul;39(7):731-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral sclerosing stromal tumor of the ovary in a premenarchal girl.
  • Sclerosing stromal tumor (SST) is a rare benign ovarian neoplasm classified as a type of sex cord stromal tumor that occurs predominantly in young patients.
  • [MeSH-major] Diagnostic Imaging / methods. Endometrial Stromal Tumors / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Child. Female. Humans. Menarche. Sclerosis / diagnosis

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 1999 Jul-Aug;23(4):555-7 [10433285.001]
  • [Cites] Korean J Radiol. 2003 Jul-Sep;4(3):194-9 [14530650.001]
  • [Cites] Eur Radiol. 1999;9(7):1335-8 [10460370.001]
  • [Cites] J Comput Assist Tomogr. 2001 Mar-Apr;25(2):201-6 [11242213.001]
  • [Cites] Gynecol Oncol. 2006 May;101(2):342-5 [16403568.001]
  • [Cites] Cancer. 1973 Mar;31(3):664-70 [4348335.001]
  • [Cites] Abdom Imaging. 2002 Sep-Oct;27(5):588-91 [12173003.001]
  • [Cites] Pediatr Radiol. 2003 Jan;33(1):56-8 [12497242.001]
  • (PMID = 19283376.001).
  • [ISSN] 1432-1998
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


86. Xiang H, Ding W, Liu F, Ren GP, Wang ZM, Zhu XZ: [Clinicopathologic analysis of mixed epithelial and stromal tumor of kidney and adult cystic nephroma]. Zhonghua Bing Li Xue Za Zhi; 2009 Jul;38(7):436-40
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic analysis of mixed epithelial and stromal tumor of kidney and adult cystic nephroma].
  • OBJECTIVE: To study the clinicopathologic features, immunophenotype and differential diagnosis of mixed epithelial and stromal tumor of kidney (MEST) and adult cystic nephroma (CN).
  • The glandular structures in 2 of the cases were partially lined by endometrial or tubal epithelium.
  • CONCLUSIONS: Both MEST and CN are uncommon renal neoplasm.
  • Most of them run a benign clinical course.
  • [MeSH-minor] Actins / metabolism. Adult. Carcinoma, Renal Cell / pathology. Desmin / metabolism. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Nephroma, Mesoblastic / pathology. Receptors, Estrogen / metabolism. Retrospective Studies. Vimentin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19781188.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ACTA2 protein, human; 0 / Actins; 0 / Desmin; 0 / Receptors, Estrogen; 0 / Vimentin
  •  go-up   go-down


87. van den Brink-Knol H, van Esch E: Spontaneous malignant mixed Müllerian tumor in a Wistar rat: a case report including immunohistochemistry. Vet Pathol; 2010 Nov;47(6):1105-10
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous malignant mixed Müllerian tumor in a Wistar rat: a case report including immunohistochemistry.
  • This report presents a rare, spontaneous, heterologous, malignant mixed Müllerian tumor observed in a 98-week-old untreated Wistar rat.
  • The solid part exhibited characteristics of a highly infiltrative adenocarcinoma, whereas the composition of the polypoid mass was heterogeneous, consisting of a variety of benign and malignant epithelial and mesenchymal elements.
  • The epithelial components included well-differentiated endometrial and squamous epithelium juxtaposed to carcinosarcomatous areas.
  • Immunohistochemical analysis further supported the diagnosis of malignant mixed Müllerian tumor.
  • [MeSH-major] Mixed Tumor, Mullerian / veterinary. Rats, Wistar. Uterine Neoplasms / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20587687.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Byrne JA, Maleki S, Hardy JR, Gloss BS, Murali R, Scurry JP, Fanayan S, Emmanuel C, Hacker NF, Sutherland RL, Defazio A, O'Brien PM: MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer; 2010;10:497
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.
  • MAL2 binds tumor protein D52 (TPD52), which is frequently overexpressed in ovarian carcinoma, but the clinical significance of MAL2 and TPD52 overexpression was unknown.
  • METHODS: Immunohistochemical analyses of MAL2 and TPD52 expression were performed using tissue microarray sections including benign, borderline and malignant epithelial ovarian tumours.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Serous / metabolism. Endometrial Neoplasms / metabolism. Neoplasm Proteins / metabolism. Ovarian Neoplasms / metabolism. Proteolipids / metabolism. Vesicular Transport Proteins / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cohort Studies. Female. Humans. Immunoenzyme Techniques. Middle Aged. Myelin and Lymphocyte-Associated Proteolipid Proteins. Neoplasm Staging. Neoplasm, Residual / metabolism. Neoplasm, Residual / pathology. Prognosis. Survival Rate. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histol Histopathol. 2004 Jul;19(3):925-33 [15168355.001]
  • [Cites] Chest. 2004 May;125(5):1843-52 [15136399.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4427-36 [15240533.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Dec 24;325(4):1115-21 [15555543.001]
  • [Cites] Oncogene. 2005 Mar 3;24(10):1794-801 [15688027.001]
  • [Cites] Mol Cancer. 2005;4:26 [16042759.001]
  • [Cites] Int J Cancer. 2005 Dec 20;117(6):1049-54 [15986428.001]
  • [Cites] Nat Clin Pract Oncol. 2005 May;2(5):246-54 [16264960.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8577-84 [16361540.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1354-62 [16452189.001]
  • [Cites] Oral Oncol. 2006 Mar;42(3):306-16 [16321566.001]
  • [Cites] Nat Genet. 2006 Apr;38(4):421-30 [16518402.001]
  • [Cites] BMC Cancer. 2006;6:92 [16608533.001]
  • [Cites] Oncogene. 2006 Nov 23;25(55):7324-32 [16751803.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):6937-45 [17145811.001]
  • [Cites] N Engl J Med. 2007 Jan 18;356(3):217-26 [17229949.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1511-7 [17192896.001]
  • [Cites] Mol Cancer Res. 2007 Feb;5(2):133-44 [17314271.001]
  • [Cites] PLoS One. 2007;2(3):e323 [17389914.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4731-9 [17699850.001]
  • [Cites] J Pathol. 2007 Sep;213(1):46-55 [17668415.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8906-13 [17875733.001]
  • [Cites] BMC Cancer. 2007;7:226 [18088415.001]
  • [Cites] BMC Syst Biol. 2008;2:2 [18173842.001]
  • [Cites] Br J Cancer. 2008 Jun 17;98(12):1999-2005 [18506145.001]
  • [Cites] Clin Cancer Res. 2008 Aug 15;14(16):5050-60 [18698023.001]
  • [Cites] Clin Cancer Res. 2008 Aug 15;14(16):5198-208 [18698038.001]
  • [Cites] Mol Cancer Res. 2008 Oct;6(10):1544-53 [18922970.001]
  • [Cites] Crit Rev Oncog. 2008;14(1):33-55 [19105569.001]
  • [Cites] BMC Cell Biol. 2009;10:7 [19175940.001]
  • [Cites] Clin Cancer Res. 2009 Apr 1;15(7):2269-80 [19293255.001]
  • [Cites] Cancer Res. 2009 May 1;69(9):3795-801 [19336569.001]
  • [Cites] Nat Rev Cancer. 2009 Jun;9(6):415-28 [19461667.001]
  • [Cites] J Proteome Res. 2009 Mar;8(3):1452-63 [19159301.001]
  • [Cites] Breast Cancer Res Treat. 2009 Jul;116(2):281-94 [18642118.001]
  • [Cites] Fertil Steril. 2010 Sep;94(4):1212-7 [19643405.001]
  • [Cites] Oncology. 2000 Jun;59(1):50-6 [10895067.001]
  • [Cites] J Biol Chem. 2001 Aug 3;276(31):28866-72 [11384973.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5895-904 [11479231.001]
  • [Cites] Genomics. 2001 Aug;76(1-3):81-8 [11549320.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12963-8 [12297621.001]
  • [Cites] J Cell Biol. 2002 Oct 14;159(1):37-44 [12370246.001]
  • [Cites] Trends Biochem Sci. 2002 Dec;27(12):599-601 [12468223.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1151-62 [12651607.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8861-8 [14695203.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Genome Res. 2004 Jun;14(6):1085-94 [15173114.001]
  • (PMID = 20846453.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MAL2 protein, human; 0 / Myelin and Lymphocyte-Associated Proteolipid Proteins; 0 / Neoplasm Proteins; 0 / Proteolipids; 0 / TPD52 protein, human; 0 / Vesicular Transport Proteins
  • [Other-IDs] NLM/ PMC2949808
  •  go-up   go-down


89. Navarro-Pelayo Lainez MM, Ramos-Font C, Rebollo Aguirre AC, Rodríguez-Fernández A, Llamas-Elvira JM: [Perivascular epithelioid tumors: Utility of the positron emission tomography with 18F-fluorodesoxyglucose (PET-TAC FDG) in their staging and follow-up]. Rev Esp Med Nucl; 2010 Sep-Oct;29(5):258-62
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Tumor epitelioide perivascular uterino. Utilidad de la tomografía por emisión de positrones con (18)F-fluordesoxiglucosa en su estadificación y seguimiento.
  • The findings suggest that since this is a rare tumor, which does not always have benign behaviour, PET-CT may be a useful diagnostic imaging procedure for staging and clinical monitoring of patients who suffer this type of tumors.
  • [MeSH-major] Endometrial Neoplasms / radionuclide imaging. Estrogens. Fluorine Radioisotopes. Fluorodeoxyglucose F18. Lung Neoplasms / secondary. Neoplasms, Hormone-Dependent / radionuclide imaging. Perivascular Epithelioid Cell Neoplasms / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier España, S.L. y SEMNIM. All rights reserved.
  • (PMID = 20462672.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Estrogens; 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


90. Paci M, Cavazza A, Annessi V, Ricchetti T, Rapicetta C, Sgarbi G: Cystic fibrohistiocytic tumor of the lung presenting as a solitary lesion. Rare Tumors; 2010;2(1):e14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic fibrohistiocytic tumor of the lung presenting as a solitary lesion.
  • Cystic fibrohistiocytic tumor of the lung is a rare neoplasm.
  • In many cases it represents a metastasis from a benign or low-grade fibrohistiocytic tumor of the skin, but occasionally it may be primary.
  • Microscopy of the apical segmentectomy showed a cystic fibrohistiocytic tumor, whereas the nodule of the lower lobe was an intraparenchymal lymph node.
  • The patient is alive with no tumor recurrence.
  • The differential diagnosis includes Langerhans cell histiocytosis, lymphangioleiomyomatosis, pleuropulmonary blastoma, and metastatic endometrial stromal sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139943.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994490
  • [Keywords] NOTNLM ; cystic fibrohistiocytic tumor / lung neoplasms / mesenchymal cystic hamartoma / mesenchymal tumors / metastases / pneumothorax
  •  go-up   go-down


91. Rabban JT, Zaloudek CJ, Shekitka KM, Tavassoli FA: Inflammatory myofibroblastic tumor of the uterus: a clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors. Am J Surg Pathol; 2005 Oct;29(10):1348-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor of the uterus: a clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors.
  • Inflammatory myofibroblastic tumor (IMT) is an indolent spindle cell proliferation that can histologically resemble various malignant mesenchymal neoplasms; however, it generally behaves as a benign or locally recurrent tumor.
  • The three other tumors grew as bulky myometrial masses with focally irregular borders and infiltrated the endometrium, parametrium, or cervical stroma.
  • Mitotic activity ranged from 0 to 2 mitotic figures per 10 high power fields (HPF) except in one tumor that focally had up to 8 mitotic figures per 10 HPF.
  • No ALK expression was identified in uterine leiomyoma (n = 7), leiomyosarcoma (n = 6), carcinosarcoma (n = 4), endometrial stromal sarcoma (n = 4), or normal uterine tissues.
  • [MeSH-minor] Adolescent. Adult. Child. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged. Protein-Tyrosine Kinases / metabolism. Receptor Protein-Tyrosine Kinases. Sarcoma / metabolism. Sarcoma / pathology

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16160478.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


92. Shaco-Levy R, Piura B: Uterine adenolipoleiomyoma: a tumor with potential of aggressive behavior. Int J Gynecol Pathol; 2008 Apr;27(2):252-7
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine adenolipoleiomyoma: a tumor with potential of aggressive behavior.
  • Histology showed the mass to be composed of benign-appearing smooth muscle, mature adipose tissue, and bland endocervical-type glands.
  • The recurrent adenolipoleiomyoma contained, in addition, benign-appearing endometrial-type glands and stroma and showed small foci of atypically proliferating endocervical-type epithelium.
  • [MeSH-minor] Female. Humans. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Uterus / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317215.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Pino M, Galleguillos C, Torres M, Sovino H, Fuentes A, Boric MA, Johnson MC: Association between MMP1 and MMP9 activities and ICAM1 cleavage induced by tumor necrosis factor in stromal cell cultures from eutopic endometria of women with endometriosis. Reproduction; 2009 Nov;138(5):837-47
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between MMP1 and MMP9 activities and ICAM1 cleavage induced by tumor necrosis factor in stromal cell cultures from eutopic endometria of women with endometriosis.
  • Endometriosis is a benign gynecological pathology in which immune system deregulation may play a role in its initiation and progression.
  • The objective of our study was to investigate the association between MMP1 and MMP9 activities and ICAM1 cleavage mediated by tumor necrosis factor (TNF) in eutopic endometrial stromal cells from women with and without (control) endometriosis during culture.
  • [MeSH-major] Endometriosis / pathology. Endometrium / pathology. Intercellular Adhesion Molecule-1 / metabolism. Matrix Metalloproteinase 1 / metabolism. Matrix Metalloproteinase 9 / metabolism. Stromal Cells / drug effects. Tumor Necrosis Factor-alpha / pharmacology. Uterine Diseases / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Uterine Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661147.001).
  • [ISSN] 1741-7899
  • [Journal-full-title] Reproduction (Cambridge, England)
  • [ISO-abbreviation] Reproduction
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 126547-89-5 / Intercellular Adhesion Molecule-1; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


94. Zhang WY, Pan Y, Zhu LR, Zhang JZ, Zhang M, Feng K, Zhou L, Yu L, Zhang XM, Ng SW: [Expression of topoisomerase III alpha in epithelial ovarian tumors of different types and relation between the expression of topoisomerase III alpha and the clinical pathology of tumor]. Zhonghua Yi Xue Za Zhi; 2005 Nov 9;85(42):2988-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of topoisomerase III alpha in epithelial ovarian tumors of different types and relation between the expression of topoisomerase III alpha and the clinical pathology of tumor].
  • OBJECTIVE: To investigate the expression status of topoisomerase IIIa in epithelial ovarian tumor and the relationship between the expression status of topoisomerase IIIa and pathological type and clinical stage of epithelial ovarian carcinoma.
  • METHODS: Immunohistochemistry was carried out in the samples of ovarian tumor obtained during operation from 169 patients, aged 28 approximately 59, 18 cases with serous cystadenoma, 30 cases with serous borderline cystadenoma, 37 serous cystadenocarcinoma, 10 cases with mucous cystadenoma, 20 mucous borderline cystadenoma, 26 mucous cystadenocarcinoma, 19 cases with endometrial carcinoma of ovary, and 9 cases with clear cell carcinoma.
  • RESULTS: The expression rate of topoisomerase IIIa was 17.9% in the benign ovarian tumors, 74.0% in the borderline cystadenoma, and 42.7% in the malignant tumors with statistical significance among them (chi(2) = 24.657, P < 0.001).
  • CONCLUSION: Topoisomerase IIIa is highly expressed in epithelial ovarian carcinoma, and its expression level is correlated with the character and type of tumor tissues.
  • [MeSH-minor] Adult. Cystadenoma, Mucinous / enzymology. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / enzymology. Cystadenoma, Serous / pathology. Female. Humans. Immunohistochemistry. Isoenzymes / biosynthesis. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16324386.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Isoenzymes; EC 5.99.1.2 / DNA Topoisomerases, Type I; EC 5.99.1.2 / DNA topoisomerase III
  •  go-up   go-down


95. Healy KA, Carney KJ, Osunkoya AO: Endometrioid adenocarcinoma in the native ureter of a renal transplant patient: case report and review of the literature. ScientificWorldJournal; 2010;10:1714-22
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endometriosis is characterized by endometrial-like tissue outside the uterus, primarily on the pelvic peritoneum, ovaries, and rectovaginal septum, and, in rare cases, within the urinary tract (1-3%).
  • Although endometriosis is a benign condition, malignant transformation of endometriosis is a well-described phenomenon.
  • Workup revealed a filling defect in the native left mid-ureter secondary to a large 2.5-cm ureteral tumor.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Endometrial Neoplasms / diagnosis. Kidney Transplantation. Ureter / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20842317.001).
  • [ISSN] 1537-744X
  • [Journal-full-title] TheScientificWorldJournal
  • [ISO-abbreviation] ScientificWorldJournal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


96. Koviazin VA, Shchelokova EE, Kostanian IA, Dranitsyna SM, Frolova II, Babichenko II: [The proapoptotic factor HLDF in the normal, hyperplastic and neoplastic endometrium]. Arkh Patol; 2007 May-Jun;69(3):23-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The proapoptotic factor HLDF in the normal, hyperplastic and neoplastic endometrium].
  • Antibodies to the factor HLDF are shown to be specific markers of apoptosis and permit the estimation of the rate of programmed cell death in the course of a normal menstrual cycle and in pathologic endometrial processes.
  • Antibodies to the HLDF factor may be used as a new immunohistochemical marker for the differential diagnosis of benign and malignant endometrial processes.
  • [MeSH-major] Biomarkers, Tumor / analysis. Endometrial Hyperplasia / diagnosis. Endometrial Neoplasms / diagnosis. Neoplasm Proteins / analysis
  • [MeSH-minor] Antibodies / immunology. Apoptosis. Endometrium / pathology. Female. Humans. Immunohistochemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17722590.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / cell differentiation factor 8.2-kDa
  •  go-up   go-down


97. Visnovský J, Galo S, Zúbor P, Hatok J, Racay P, Danko J: [Semiquantitative analysis of mRNA aromatase expression in eutopic endometrium as a diagnostic marker of endometriosis and estrogen dependent diseases]. Ceska Gynekol; 2008 Jul;73(4):213-7
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Semiquantitative analysis of mRNA aromatase expression in eutopic endometrium as a diagnostic marker of endometriosis and estrogen dependent diseases].
  • OBJECTIVE: To determine clinical benefits of mRNA aromatase expression in entopic endometrium as a diagnostic marker of endometriosis.
  • METHODS: The expression of mRNA aromatase of eutopic endometrium was determined among women who underwent laparoscopy or laparotomy due to pelvic pain, infertility or benign pelvic tumor.
  • By the presence of estrogen-dependent diseases- endometriosis, myomas or endometrial hyperplasia 18 women were compared to 5 disease free women.
  • CONCLUSION: Aromatase expression in eutopic endometrium is a good diagnostic marker for endometriosis.

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18711959.001).
  • [ISSN] 1210-7832
  • [Journal-full-title] Ceska gynekologie
  • [ISO-abbreviation] Ceska Gynekol
  • [Language] SLO
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Estrogens; 0 / RNA, Messenger; EC 1.14.14.1 / Aromatase
  •  go-up   go-down


98. Abdel-Azeez HA, Labib HA, Sharaf SM, Refai AN: HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev; 2010;11(1):111-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To evaluate the utility of novel serum tumor markers, HE4 and mesothelin either alone or in combination with CA125 in diagnosis and early detection of ovarian carcinoma in patients with pelvic masses.
  • RESULTS: Of 65 patients with pelvic masses; 41 had histologically diagnosed ovarian cancer, and 24 had benign ovarian diseases.
  • The studied tumor markers were significantly increased in malignant compared to benign cases and healthy subjects, and in benign cases compared to healthy subjects (p<0.001).
  • [MeSH-major] Biomarkers, Tumor / blood. Epididymal Secretory Proteins / metabolism. Membrane Glycoproteins / blood. Ovarian Neoplasms / blood. Pelvic Neoplasms / blood
  • [MeSH-minor] Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / pathology. CA-125 Antigen / blood. Case-Control Studies. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / blood. Endometrial Neoplasms / pathology. Female. GPI-Linked Proteins. Humans. Middle Aged. Neoplasm Staging. Prognosis. ROC Curve. Sensitivity and Specificity. beta-Defensins

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20593939.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / beta-Defensins; 0 / mesothelin
  •  go-up   go-down


99. Bershteĭn LM, Poroshina TE, Vasil'ev DA, Orlova AV: [Autoantibodies to steroid-producing ovarian cells in cancer patients]. Vopr Onkol; 2008;54(5):602-5
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our investigation included 158 women, aged 23-73: patients with tumors of the ovary, breast and endometrium--117 and subjects without oncological pathology--41.
  • Autoantibodies to microsomal fraction of follicular ovarian cells (> 500 Unit/ml) in healthy subjects were revealed 8.3% while in patients with ovarian, breast and endometrial malignancies (without significant differences between benign and malignant tumors) in 33.30%, 45.60% and 25.0%, respectively.
  • Higher level of anti-ovarian autoantibodies involved an inverse correlation between blood levels of FSH and estradiol in ovarian and endometrial carcinoma patients.
  • [MeSH-major] Autoantibodies / blood. Biomarkers, Tumor / blood. Breast Neoplasms / immunology. Endometrial Neoplasms / immunology. Gonadal Steroid Hormones / biosynthesis. Ovarian Neoplasms / immunology. Ovary / immunology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19069474.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / Gonadal Steroid Hormones; 4TI98Z838E / Estradiol; 9002-68-0 / Follicle Stimulating Hormone; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


100. Czernobilsky B: Uterine tumors resembling ovarian sex cord tumors: an update. Int J Gynecol Pathol; 2008 Apr;27(2):229-35
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors of the uterus resembling ovarian sex cord tumors were reported by Clement and Scully in 1976 and were divided in 2 groups: group 1, endometrial stromal tumors, and group 2, mural uterine tumors-both with elements resembling ovarian sex cord tumors.
  • In the former, the sex cord component constitutes a minor portion of an endometrial stromal neoplasm, whereas in the latter, it is the predominant or exclusive component of a uterine wall lesion composed of a variety of mesenchymal elements.
  • An origin from endometrial stromal cells, adenomyosis, stromal myosis, endometriosis, or multipotential cells within the myometrium was postulated in both groups of tumors.
  • In group 1 tumors, the prognosis depends on the type, grade, and stage of the underlying stromal neoplasm.
  • Group 2 tumors seemed to be benign, although because of the occasional recurrence of these tumors, they should be considered of low-grade malignant potential.
  • Eventually, the abbreviation ESTSCLE, or endometrial stromal tumors with sex cord-like elements, was given to group 1 tumors, whereas UTROSCT, or uterine tumor resembling ovarian sex cord tumor, was used for group 2 tumors.
  • Positivity for calretinin and at least for 1 of the other above-mentioned markers may thus confirm the diagnosis of UTROSCT.
  • Endometrial stromal tumors with sex cord-like elements, on the other hand, usually express only 1 sex cord marker, mostly calretinin.
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cell Differentiation. Diagnosis, Differential. Endometrial Stromal Tumors / diagnosis. Endometrial Stromal Tumors / pathology. Female. Humans

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317219.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 40
  •  go-up   go-down






Advertisement